Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
References AAFP (American Academy of Family Physicians). 2006a. Board of Directors Report V to the 2006 Congress of Delegates. Leawood, KS: AAFP. http://www.aafp.org/online/etc/ medialib/aafp_org/documents/about/congress/2006/bd-rpts/brdrptv.Par.0001.File.tmp/ Board%20Report%20V%20on%20AAFP%20and%20Nondues%20Revenue.pdf (ac- cessed April 8, 2009). AAFP. 2006b. Full Disclosure for CME Activities: American Family Physician authors. Leawood, KS: AAFP. http://www.aafp.org/online/etc/medialib/aafp_org/documents/ news_pubs/afp/afpconflictofinterestform.Par.0001.File.tmp/COI-form-2008.pdf (accessed August 12, 2008). AAMC (Association of American Medical Colleges). 1998. Guidelines for Dealing with Fac- ulty Conflicts of Commitment and Conflicts of Interest in Research. Adopted by AAMC Executive Council, February 1990; revised, January 1998. Washington, DC: AAMC. AAMC. 2001. Protecting Subjects, Preserving Trust, Promoting Progress: Policy and Guide- lines for the Oversight of Individual Financial Interests in Human Subjects Research. Washington, DC: AAMC. http://www.aamc.org/research/coi/firstreport.pdf (accessed June 23, 2008). AAMC. 2002. Protecting Subjects, Preserving Trust, Promoting Progress II: Principles and Recommendations for Oversight of an Institutionâs Financial Interests in Human Subjects Research. Washington, DC: AAMC. http://www.aamc.org/research/coi/2002coireport. pdf (accessed September 19, 2008). AAMC. 2004. Clinical Trial Contracts: A Discussion of Four Selected Provisions. Wash- ington, DC: AAMC. https://services.aamc.org/Publications/showfile.cfm?file=version6. pdf&prd_id=76&prv_id=75&pdf_id=6 (accessed February 21, 2009). AAMC. 2008a. Table 3: applicants to U.S. medical schools by state of legal residence, 1997- 2008. In AAMC Facts. Washington, DC: AAMC. http://www.aamc.org/data/facts/2008/ 2008slr.htm (accessed March 22, 2009). AAMC. 2008b. Compact Between Biomedical Graduate Students and Their Research Advi- sors. Washington, DC: AAMC. https://services.aamc.org/Publications/showfile.cfm?file= version127.pdf (accessed February 18, 2009). AAMC. 2008c. Industry Funding of Medical Education. Washington, DC: AAMC. https:// services.aamc.org/Publications/showfile.cfm?file=version114.pdf&prd_id=232 (accessed October 10, 2008). 240
REFERENCES 241 AAMC. 2008d. Medical Schools. Washington, DC: AAMC. http://www.aamc.org/ medicalschools.htm (accessed November 17, 2008). AAMC. 2008e. Table 26: total active enrollment by U.S. medical school and sex, 2003-2008. In AAMC Facts. Washington, DC: AAMC. http://www.aamc.org/data/facts/2008/school- enrll0308.htm (accessed March 4, 2009). AAMC-AAU (Association of American Universities). 2008. Protecting Patients, Preserving Integrity, Advancing Health: Accelerating the Implementation of COI Policies in Hu- man Subjects Research. Report of the AAMC-AAU Advisory Committee on Financial Conflicts of Interest in Human Subjects Research. Washington, DC: AAMC. https:// services.aamc.org/Publications/showfile.cfm?file=version107.pdf&prd_id=220&prv_ id=268&pdf_id=107 (accessed September 19, 2008). AAU. 2001. Report on Individual and Institutional Financial Conflict of Interest. Report of the AAU Task Force on Research Accountability. Washington, DC: AAU. http://www. aau.edu/research/COI.01.pdf (accessed August 1, 2008). AAUP (American Association of University Professors). 2004. Statement on Corporate Fund- ing of Academic Research. Washington, DC: AAUP. http://www.aaup.org/NR/rdonlyres/ 7B12F7B9-FA00-44DD-999F-FFA21AAE1F39/0/CorporateFundingonAcaResearch.pdf (accessed April 17, 2009). AAUP/ACE (American Council on Education). 1965. On preventing conflicts of interest in government-sponsored research at universities; a joint statement of the Council of the American Association of University Professors and The American Council on Education. AAUP Bulletin 51:42-43. ABIM (American Board of Internal Medicine) Foundation, ACP-ASIM (American College of Physicians-American Society of Internal Medicine) Foundation, and European Federation of Internal Medicine. 2002. Medical professionalism in the new millennium: a physician charter. Annals of Internal Medicine 136(3):243-246. ABMS (American Board of Medical Specialties). 2007. American Board of Medical Special- ties Board Certification Editorial Background. Evanston, IL: ABMS. http://www.abms. org/news_and_events/media_newsroom/pdf/abms_editorialbackground.pdf (accessed September 25, 2008). ACC/AHA (American College of Cardiology/American Heart Association). 2009. Methodol- ogy Manual for ACC/AHA Guideline Writing Committees. Report of the ACC/AHA Task Force on Practice Guidelines. Washington, DC: ACC/AHA. http://www.acc.org/ qualityandscience/clinical/manual/pdfs/methodology.pdf (accessed April 8, 2009). ACCME (Accreditation Council for Continuing Medical Education). 2005. ACCMEâs Glossary of Terms and Abbreviations. Chicago, IL: ACCME. http://cores33webs.mede.uic.edu/ capp/public/public_docs/accme_glossary_of_terms.pdf (accessed October 22, 2008). ACCME. 2008a. ACCME Annual Report Data 2007. Chicago, IL: ACCME. http://www. accme.org/dir_docs/doc_upload/207fa8e2-bdbe-47f8-9b65-52477f9faade_uploaddocu- ment.pdf (accessed October 22, 2008). ACCME. 2008b. Accredited CME Is Education That Matters to Patient Care. Chicago, IL: ACCME. http://www.accme.org/dir_docs/doc_upload/d6b96a50-084c-485b-b71a- 6b405b9c07d8_uploaddocument.pdf (accessed December 30, 2008). ACCME. 2008c. Executive Summary of the November 2008 Meetings of the ACCME Board of Directors. Chicago, IL: ACCME. http://www.accme.org/dir_docs/whats_new/607a2906- dda2-4e9d-b6cf-7922723b46a1_uploadfile.pdf (accessed February 22, 2009). ACCME. 2008d. For Comment: ACCME Proposes Additional Features of Independence in Accredited Continuing Medical Education. Chicago, IL: ACCME. http://www.accme. org/dir_docs/doc_upload/d64b68f6-9525-43af-9074-719f92ad7c97_uploaddocument. pdf (accessed October 7, 2008).
242 CONFLICT OF INTEREST ACCME. 2009. List of Accredited Providers. Chicago, IL: ACCME. http://www.accme.org/ index.cfm/fa/home.popular/popular_id/66be063a-8081-40f2-9615-042a733485d8.cfm (accessed March 23, 2009). ACE (American Council on Education). 2007. Working Paper on Conflict of Interest. Wash- ington, DC: ACE. http://www.acenet.edu/AM/Template.cfm?Section=Home&TEMPLAT E=/CM/ContentDisplay.cfm&CONTENTID=26137 (accessed April 17, 2009). ACGME (Accreditation Council for Graduate Medical Education). 2002. Principles to Guide the Relationship Between Graduate Medical Education and Industry. Chicago, IL: ACGME. http://www.acgme.org/acWebsite/positionPapers/pp_GMEGuide.pdf (accessed August 12, 2008). ACGME. 2007a. ACGME Institutional Requirements. Chicago, IL: ACGME. http://www. acgme.org/acWebsite/irc/irc_IRCpr07012007.pdf (accessed September 3, 2008). ACGME. 2007b. The ACGME at a Glance. Chicago, IL: ACGME. http://www.acgme.org/ac- Website/newsRoom/newsRm_acGlance.asp (accessed September 3, 2008). ACGME. 2008. Glossary of Terms. Chicago, IL: ACGME. http://www.acgme.org/acwebsite/ about/ab_acgmeglossary.pdf (accessed August 12, 2008). ACIP (Advisory Committee on Immunization Practices). 2007. Recommended adult im- munization schedule: United States, October 2007-September 2008. Annals of Internal Medicine 147(10):725-729. ACN (American College of Neuropsychopharmacology). 2004. Executive summary. In Pre- liminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth. Nashville, TN: ACN. http://www.acnp.org/asset.axd?id=aad01592-01b2-4672-ad28-119537460ffa (accessed December 15, 2008). ACR (American College of Radiology). 2007a. ACR Practice Guideline for the Performance of Total Body Irradiation. Reston, VA: ACR. ACR (American College of Rheumatology). 2007b. Code of Ethics of the American College of Rheumatology, Inc. http://www.rheumatology.org/about/codeofethics/index.pdf (accessed September 2, 2008). Adair, R. F., and L. R. Holmgren. 2005. Do drug samples influence resident prescribing behav- ior? A randomized trial. American Journal of Medicine 118(8):881-884. AdvaMed (Advanced Medical Technology Association). 2008. Code of Ethics on Interactions with Health Care Professionals. Effective July 1, 2009. Washington, DC: AdvaMed. http://www.advamed.org/NR/rdonlyres/61D30455-F7E9-4081-B219-12D6CE347585/0/ AdvaMedCodeofEthicsRevisedandRestatedEffective20090701.pdf (accessed February 9, 2009). AFMI (Annals of Family Medicine, Inc.). 2008. Annals of Family Medicine Manuscript Agreement. Leawood, KS: AFMI. http://www.annfammed.org/misc/pdfsanddocs/ ManuscriptAgreement08.doc (accessed December 30, 2008). AGREE (Appraisal of Guidelines Research and Evaluation) Collaboration. 2003. AGREE Instrument Training Manual. http://www.agreecollaboration.org/pdf/aitraining.pdf (ac- cessed February 23, 2009). AHRP (Alliance for Human Research Protection). 2006. Vioxx Redux: FDA on the Sidelines as Marketing Subsumes Evidence: Surviving Sepsis-NEJM. New York, NY: AHRP. http:// www.ahrp.org/cms/index2.php?option=com_content&do_pdf=1&id=366 (accessed April 25, 2008). AJN (American Journal of Nephrology). 2008. Guidelines for Authors. http://content.karger. com/ProdukteDB/produkte.asp?Aktion=JournalGuidelines&ProduktNr=223979 (ac- cessed September 15, 2008). Alpert, J. S., S. Furman, and L. Smaha. 2002. Conflicts of interest: science, money, and health. Archives of Internal Medicine 162(6):635-637.
REFERENCES 243 AMA (American Medical Association). 2002. Opinion E-8.061: Clarifying Addendum [to Opinion 8.061, âGifts to physicians from industryâ]. Chicago, IL: AMA. http://www. ama-assn.org/ama/pub/category/4263.html (accessed September 2, 2008). AMA. 2006. The Physicianâs Recognition Award and Credit System: Information for Accred- ited Providers and Physicians. Chicago, IL: AMA. http://www.ama-assn.org/ama1/pub/ upload/mm/455/pra2006.pdf (accessed September 15, 2008). AMA. 2007. Opinion 8.047: industry representatives in clinical settings. Code of Medi- cal Ethics. http://www.ama-assn.org/ama1/pub/upload/mm/Code_of_Med_Eth/opinion/ opinion8047.html (accessed April 8, 2009). AMA. 2008a. Continuing medical education for licensure reregistration. In State Medical Licensure Requirements and Statistics 2009. Chicago, IL: AMA. http://www.ama-assn. org/ama1/pub/upload/mm/40/table16-2009.pdf (accessed February 10, 2009) AMA. 2008b. Guidance on New Procedures for CME. Chicago, IL: AMA. http://www. ama-assn.org/ama/pub/education-careers/continuing-medical-education/physicians- recognition-award-credit-system/cme-help/guidance-new-procedure-cme.shtml (accessed February 16, 2009). AMA. 2008c. Reference Committee Highlights: 2008 Annual Meeting for the AMA House of Delegates. Chicago, IL: AMA. http://www.ama-assn.org/ama1/pub/upload/mm/471/ refcomhighlights.pdf (accessed January 29, 2009). AMSA (American Medical Student Association). 2008a. Focus on Pharm Free. Reston, VA: AMSA. http://www.amsa.org/prof/focus.cfm (accessed August 1, 2008). AMSA. 2008b. PharmFree Scorecard 2008. Reston, VA: AMSA. http://amsascorecard.org/ (accessed September 19, 2008). Ancker, J. S., and A. Flanagin. 2007. A comparison of conflict of interest policies at peer- reviewed journals in different scientific disciplines. Science and Engineering Ethics 13(2):147-157. Andersen, M., J. Kragstrup, and J. Sondergaard. 2006. How conducting a clinical trial affects ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ physiciansâ guideline adherence and drug preferences. Journal of the American Medical Association 295(23):2759-2764. Angel, J. E. 2003. Industry sponsorship of continuing medical education. Journal of the Ameri- can Medical Association 290(9):1149-1150; author reply 1150. APA (American Psychiatric Association). 2008. Minutes. APA Board of Trustees meeting, Arlington, VA, March 9-10. Arlington, VA: APA. Arenberg, D. 2007. Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl.):306S-313S. Armon, C., C. E. Argoff, J. Samuels, and M. M. Backonja. 2007. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurol- ogy 68(10):723-729. Armstrong, D. 2005. Surgery journal threatens ban for authorsâ hidden conflicts. Wall Street Journal, December 28, B1. Armstrong, D. 2006. Medical reviews face criticism over lapses. Wall Street Journal, July 19, B1, B2. Arnau, J. M., A. Vallano, A. Lopez, F. Pellise, M. J. Delgado, and N. Prat. 2006. A critical review of guidelines for low back pain treatment. European Spine Journal 15(5):543-553. ASCO (American Society of Clinical Oncology). 2007. Journal of Clinical Oncology Au- thor Disclosure Declaration. Alexandria, VA: ASCO. http://jco.ascopubs.org/misc/jco_ disclosure_contribution.pdf (accessed November 11, 2008). ASCO. 2008. American Society of Clinical Oncology Guideline Procedures Manual. Al- exandria, VA: ASCO. http://www.asco.org/ASCO/Quality+Care+%26+Guidelines/ Practice+Guidelines/development+process (accessed February 27, 2009).
244 CONFLICT OF INTEREST ASH (American Society of Hematology). 2008. Principles, policies, and procedures related to conflict-of-interest. Written statement given to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC. The Associated Press. 2008. Medical Experts Fight Drug Industry Influence. http://www.ctv. ca/servlet/ArticleNews/story/CTVNews/20080911/medical_schools_080911/20080911? hub=Health (accessed December 15, 2008). ATS (American Thoracic Society). 2008. Policy on Management of Conflict of Interest in Official ATS Documents, Projects, and Conferences. New York, NY: ATS. http://www. thoracic.org/sections/about-ats/coi-management/resources/coi-policy.pdf (accessed August 19, 2008). AUTM (Association of University Technology Managers). 2007. AUTM U.S. Licensing Activity Sur- vey: FY2006. Deerfield, IL: AUTM. http://www.autm.net/Content/NavigationMenu/ÂSurveys/ LicensingSurveysAUTM/FY2006LicensingActivitySurvey/AUTM_06_US_LSS_FNL.pdf (ac- cessed January 10, 2009). Avorn, J. 2006. Dangerous deceptionâhiding the evidence of adverse drug effects. New Eng- land Journal of Medicine 355(21):2169-2171. Avorn, J., and S. B. Soumerai. 1983. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based âdetailing.â New England Journal of Medicine 308(24):1457-1463. Ayanian, J. Z., M. B. Landrum, S. L. Normand, E. Guadagnoli, and B. J. McNeil. 1998. Rating the appropriateness of coronary angiographyâdo practicing physicians agree with an expert panel and with each other? New England Journal of Medicine 338(26):1896-1904. Ayres, C. G., and H. M. Griffith. 2007. Perceived barriers to and facilitators of the implemen- tation of priority clinical preventive services guidelines. American Journal of Managed Care 13(3):150-155. Bahtsevani, C., G. Uden, and A. Willman. 2004. Outcomes of evidence-based clinical practice guidelines: a systematic review. International Journal of Technology Assessment in Health Care 20(4):427-433. Bailey, R. 2008. Scrutinizing Industry-Funded Science: The Crusade Against Conflicts of Interest. New York: American Council on Science and Health. http://www.acsh.org/ docLib/20080401_scrutinizing.pdf (accessed October 10, 2008). Barnes, B. E., J. G. Cole, C. T. King, R. Zukowski, T. Allgier-Baker, D. M. Rubio, and L. E. Thorndyke. 2007. A risk stratification tool to assess commercial influences on continuing medical education. Journal of Continuing Education in the Health Profes- sions 27(4):234-240. Barnes, D. E., and L. A. Bero. 1998. Why review articles on the health effects of pas- sive smoking reach different conclusions. Journal of the American Medical Association 279(19):1566-1570. Baru, J. S., D. A. Bloom, K. Muraszko, and C. E. Koop. 2001. John Holterâs shunt. Journal of the American College of Surgeons 192(1):79-85. Battista, R. N., and M. J. Hodge. 1995. Setting priorities and selecting topics for clinical prac- tice guidelines. Canadian Medical Association Journal 153(9):1233-1237. Baumann, M. H., S. Z. Lewis, and D. Gutterman. 2007. ACCP evidence-based guideline de- velopment: a successful and transparent approach addressing conflict of interest, funding, and patient-centered recommendations. Chest 132(3):1015-1024. Baxter, P. 2006. Medicine and the pharmaceutical industry. Developmental Medicine and Child Neurology 48(8):627. Beauchamp, T. L., and J. F. Childress. 2009. Principles of Biomedical Ethics, 6th ed. New York: Oxford University Press.
REFERENCES 245 Bekelman, J. E., Y. Li, and C. P. Gross. 2003. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. Journal of the American Medical Association 289(4):454-465. Bellin, M., S. McCarthy, L. Drevlow, and C. Pierach. 2004. Medical studentsâ exposure to pharmaceutical industry marketing: a survey at one U.S. medical school. Academic Medicine 79(11):1041-1045. Benet, L. Z. 2008. Perspectives on financial relationships and conflicts of interest in basic and early stage translational research: reflections on 28 years of organized COI experience at UCSF. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. Bennett, C. L., M. R. Somerfield, D. G. Pfister, C. Tomori, S. Yakren, and P. B. Bach. 2003. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. Journal of Clinical Oncology 21(5):937-941. Bennett, K. J., D. L. Sackett, R. B. Haynes, V. R. Neufeld, P. Tugwell, and R. Roberts. 1987. A controlled trial of teaching critical appraisal of the clinical literature to medical students. Journal of the American Medical Association 257(18):2451-2454. Benz, E. 2008. Untitled. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. Bero, L. 2008. âExperimentalâ institutional models for corporate funding of academic re- search: unknown effects on the research enterprise. Journal of Clinical Epidemiology 61(7):629-633. Bero, L., and D. Rennie. 1996. Influences on the quality of published drug studies. Interna- tional Journal of Technology Assessment in Health Care 12(2):209-237. Bero, L., A. Galbraith, and D. Rennie. 1992. The publication of sponsored symposiums in medical journals. New England Journal of Medicine 327(16):1135-1140. Bero, L., S. Glantz, and M. K. Hong. 2005. The limits of competing interest disclosures. Tobacco Control 14(2):118-126. Bero, L., F. Oostvogel, P. Bacchetti, and K. Lee. 2007. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Medicine 4(6):e184. Berwick, D. M. 1998. Developing and testing changes in delivery of care. Annals of Internal Medicine 128(8):651-656. Bhargava, N., J. Qureshi, and N. Vakil. 2007. Funding source and conflict of interest disclo- sures by authors and editors in gastroenterology specialty journals. American Journal of Gastroenterology 102(6):1146-1150. Bimber, B. 1996. The Politics of Expertise in Congress: The Rise and Fall of the Office of Technology Assessment. Albany, NY: State University of New York Press. Bird, S. J., and R. E. Spier. 2005. The complexity of competing and conflicting interests. Sci- ence and Engineering Ethics 11(4):515-517. Blake, R. L., Jr., and E. K. Early. 1995. Patientsâ attitudes about gifts to physicians from phar- maceutical companies. Journal of the American Board of Family Practice 8(6):457-464. Blumenthal, D. 2004. Doctors and drug companies. New England Journal of Medicine 351(18):1885-1890. Blumenthal, D., E. G. Campbell, N. Causino, and K. S. Louis. 1996a. Participation of life- science faculty in research relationships with industry. New England Journal of Medicine 335(23):1734-1739. Blumenthal, D., N. Causino, E. Campbell, and K. S. Louis. 1996b. Relationships between academic institutions and industry in the life sciencesâan industry survey. New England Journal of Medicine 334(6):368-373.
246 CONFLICT OF INTEREST Blumenthal, D., E. G. Campbell, M. S. Anderson, N. Causino, and K. S. Louis. 1997. With- holding research results in academic life science. Evidence from a national survey of faculty. Journal of the American Medical Association 277(15):1224-1228. Bodenheimer, T. 2000. Uneasy allianceâclinical investigators and the pharmaceutical industry. New England Journal of Medicine 342(20):1539-1544. Bodenheimer, T., R. A. Berenson, and P. Rudolf. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2007. The primary care-specialty income gap: why it matters. Annals of Internal Medicine 146(4):301-306. Bok, D. 2003. Universities in the Marketplace. Princeton, NJ: Princeton University Press. Boltri, J. M., E. R. Gordon, and R. L. Vogel. 2002. Effect of antihypertensive samples on physician prescribing patterns. Family Medicine 34(10):729-731. Boluyt, N., C. R. Lincke, and M. Offringa. 2005. Quality of evidence-based pediatric guide- lines. Pediatrics 115(5):1378-1391. Bombardier, C., L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, et al. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in pa- tients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 343(21):1520-1528, 2 p following 1528. Bond, E. C., and S. Glynn. 1995. Recent trends in support for biomedical research and devel- opment. In Sources of Medical Technology: Universities and Industry. Washington, DC: National Academy Press. Borgert, C. J. 2007. Conflict of interest or contravention of science? Regulatory Toxicology and Pharmacology 48(1):4-5. Borie, D. C., J. J. OâShea, and P. S. Changelian. 2004. JAK3 inhibition, a viable new modal- ity of immunosuppression for solid organ transplants. Trends in Molecular Medicine 10(11):532-541. Bossuyt, P. M., J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou, L. M. Irwig, J. G. Lijmer, et al. 2003. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clinical Chemistry 49(1):1-6. Boston University. 2007. Policies for Interactions Among Clinicians at Boston Medical Center and Boston University School of Medicine and Representatives of the Healthcare Indus- try. Boston, MA: Boston University, http://www.bu.edu/cms/www.bumc.bu.edu/busm- od/files/Images/Policies/BMC-BUSM%20Industry%20Interactions%20_July%2026_.pdf (accessed September 25, 2008). Bowman, M. A. 1986. The impact of drug company funding on the content of continuing med- ical education. Journal of Continuing Education in the Health Professions 6(1):66-69. Bowman, M. A., and D. L. Pearle. 1988. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions 8(1):13-20. Boyd, E. A. 2008. Individual and organizational financial relationships with industry: what do we know? Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. Boyd, E. A., and L. A. Bero. 2000. Assessing faculty financial relationships with industry: a case study. Journal of the American Medical Association 284(17):2209-2214. Boyd, E. A., and L. A. Bero. 2006. Improving the use of research evidence in guideline develop- ment. 4. Managing conflicts of interests. Health Research Policy and Systems 4:16. Boyd, E. A., and L. A. Bero. 2007. Defining financial conflicts and managing research rela- tionships: an analysis of university conflict of interest committee decisions. Science and Engineering Ethics 13(4):415-435. Boyd, E. A., M. K. Cho, and L. A. Bero. 2003. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Academic Medicine 78(8):769-774.
REFERENCES 247 Boyd, E. A., S. Lipton, and L. A. Bero. 2004. Implementation of financial disclosure policies to manage conflicts of interest. Health Affairs 23(2):206-214. Brandeis, L. D. 1914. What publicity can do. In Other Peopleâs Money and How the Bankers Use It. New York: Frederick A Stokes Company. Braunwald, E., A. S. Fauci, D. Kasper, S. Hauser, D. Longo, and J. L. Jameson. 2001. Harri- sonâs Principles of Internal Medicine, vol. 2. New York: McGraw-Hill Professional. Bravo, N. R. 2008. Directorâs Column: Managing Financial Conflicts of Interests. Bethesda, MD: Office of Extramural News, National Institutes of Health. http://nexus.od.nih.gov/ nexus/nexus.aspx?ID=81&Month=6&Year=2008 (accessed December 2, 2008). Brennan, T. A., and M. M. Mello. 2007. Sunshine laws and the pharmaceutical industry. Journal of the American Medical Association 297(11):1255-1257. Brennan, T. A., D. J. Rothman, L. Blank, D. Blumenthal, S. C. Chimonas, J. J. Cohen, J. Goldman, et al. 2006. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. Journal of the American Medical Association 295(4):429-433. Brewer, D. 1998. The effect of drug sampling policies on residentsâ prescribing. Family Medi- cine 30(7):482-486. Brody, B. 2006a. Intellectual property and biotechnology: the U.S. internal experienceâPart I. Kennedy Institute of Ethics Journal 16(1):1-37. Brody, B. 2006b. Intellectual property and biotechnology: the U.S. internal experienceâPart II. Kennedy Institute of Ethics Journal 16(2):105-128. Brody, H. 2007. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham, MD: Rowman & Littlefield Publishers, Inc. Brotzman, G. L., and D. H. Mark. 1993. The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities. Journal of General Internal Medicine 8(3):130-134. Budiansky, S. 1983. Academic interest conflicts: laxity of Californian practice. Nature 301(5896):102. Burgers, J. S., R. Grol, N. S. Klazinga, M. Makela, and J. Zaat. 2003. Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. International Journal for Quality in Health Care 15(1):31-45. Burton, T. M. 2006. Amid alarm bells, a blood substitute keeps pumping; ten in trial have heart attacks, but data arenât published; FDA allows a new study; doctorsâ pleas are ignored. Wall Street Journal, February 22, A1, A12. Business Wire. 2008. National study by PeopleMetrics Rx confirms importance of emotional connection between pharmaceutical sales reps and physicians. Business Wire, August 11. http://www.reuters.com/article/pressRelease/idUS168653+11-Aug-2008+BW20080811 (accessed September 25, 2008). Cain, D., G. Loewenstein, and D. Moore. 2005. The dirt on coming clean: the perverse effects of disclosing conflicts of interest. Journal of Legal Studies 34:1-25. Camilleri, M., G. L. Gamble, S. L. Kopecky, M. B. Wood, and M. L. Hockema. 2005. Prin- ciples and process in the development of the Mayo Clinicâs individual and institutional conflict of interest policy. Mayo Clinic Proceedings 80(10):1340-1346. Campbell, E. G., and D. Blumenthal. 2000. Academic industry relationships in biotechnology: a primer on policy and practice. Cloning 2(3):129-136. Campbell, E. G., K. S. Louis, and D. Blumenthal. 1998. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. Journal of the American Medical As- sociation 279(13):995-999. Campbell, E. G., B. R. Clarridge, M. Gokhale, L. Birenbaum, S. Hilgartner, N. A. Holtzman, and D. Blumenthal. 2002. Data withholding in academic genetics: evidence from a na- tional survey. Journal of the American Medical Association 287(4):473-480.
248 CONFLICT OF INTEREST Campbell, E. G., J. B. Powers, D. Blumenthal, and B. Biles. 2004. Inside the triple helix: tech- nology transfer and commercialization in the life sciences. Health Affairs 23(1):64-76. Campbell, E. G., J. S. Weissman, C. Vogeli, B. R. Clarridge, M. Abraham, J. E. Marder, and G. Koski. 2006. Financial relationships between institutional review board members and industry. New England Journal of Medicine 355(22):2321-2329. Campbell, E. G., R. L. Gruen, J. Mountford, L. G. Miller, P. D. Cleary, and D. Blumenthal. 2007a. A national survey of physician-industry relationships. New England Journal of Medicine 356(17):1742-1750. Campbell, E. G., J. S. Weissman, S. Ehringhaus, S. R. Rao, B. Moy, S. Feibelmann, and Susan Dorr Goold. 2007b. Institutional academic-industry relationships. Journal of the Ameri- can Medical Association 298(15):1779-1786. Campbell, S. M., M. Hann, M. O. Roland, J. A. Quayle, and P. G. Shekelle. 1999. The effect of panel membership and feedback on ratings in a two-round Delphi survey: results of a randomized controlled trial. Medical Care 37(9):964-968. Campbell, W. A. 2007. The high cost of free lunch. Obstetrics and Gynecology 110(4):931- 932; author reply 932-933. Caplan, R. M. 1996. History of the Society of Medical College Directors of Continuing Medi- cal Education (SMCDCME): the first twelve years, 1976-1988. The Journal of Continu- ing Education in the Health Professions 16:14-24. Carlat, D. 2007. Dr. Drug Rep. The New York Times, November 25, Sec. 6, p. 64. Carlson, G. A., P. S. Jensen, R. L. Findling, R. E. Meyer, J. Calabrese, M. P. DelBello, G. Emslie, et al. 2003. Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: report of a consensus conference. Journal of Child and Adolescent Psychopharmacology 13(1):13-27. Carpenter, D. In press. The ambiguous emergence of an organizational identity: pharmaceuti- cal regulation at the FDA, 1947-1961. In Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, edited by D. Carpenter. Princeton, NJ: Princeton University Press. http://www.fas.harvard.edu/~polecon/EmergenceofAmerican PharmceuticalRegulation.pdf (accessed February 10, 2009). Carroll, A. E., R. C. Vreeman, J. Buddenbaum, and T. S. Inui. 2007. To what extent do educa- tional interventions impact medical traineesâ attitudes and behaviors regarding industry- trainee and industry-physician relationships? Pediatrics 120(6):e1528-e1535. Cassell, G. 2008. Untitled. Presentation for Eli Lilly and Company to the Institute of Medi- cine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. Cates, J. R., D. N. Young, D. S. Bowerman, and R. C. Porter. 2006. An independent AGREE evaluation of the Occupational Medicine Practice Guidelines. The Spine Journal 6(1): 72-77. CBO (Congressional Budget Office). 1986. Physician Reimbursement Under Medicare: Op- tions for Change. Washington, DC: CBO. http://www.cbo.gov/ftpdocs/59xx/doc5967/ doc13b-Entire.pdf (accessed September 25, 2008). CBO. 2007. Research on the Comparative Effectiveness of Medical Treatments: Options for an Expanded Federal Role. Testimony by Director Peter R. Orszag before the House Ways and Means Subcommittee on Health, June 12. http://www.cbo.gov/ftpdocs/82xx/ doc8209/Comparative_Testimony.pdf. Cech, T. R., and J. S. Leonard. 2001. Conflicts of interestâmoving beyond disclosure. Science 291(5506):989. CEJA (Council on Ethical and Judicial Affairs, American Medical Association). 2008. Industry Support of Professional Education in Medicine. CEJA Report 1-A-08. Chicago, IL: CEJA. http://www.acme-assn.org/advocacy_pg/ceja1.doc (accessed September 15, 2008).
REFERENCES 249 Chabner, B. A. 2008. Conflict of interest: in the eye of the beholder? The Oncologist 13(3): 212-213. Chaillet, N., E. Dube, M. Dugas, F. Audibert, C. Tourigny, W. D. Fraser, and A. Dumont. 2006. Evidence-based strategies for implementing guidelines in obstetrics: a systematic review. Obstetrics and Gynecology 108(5):1234-1245. Chan, A. W., A. Hrobjartsson, M. T. Haahr, P. C. Gotzsche, and D. G. Altman. 2004a. Empirical evidence for selective reporting of outcomes in randomized trials: compari- son of protocols to published articles. Journal of the American Medical Association 291(20):2457-2465. Chan, A. W., K. Krleza-Jeric, I. Schmid, and D. G. Altman. 2004b. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal 171(7):735-740. Changelian, P. S., D. Moshinsky, C. F. Kuhn, M. E. Flanagan, M. J. Munchhof, T. M. Harris, J. L. Doty, J. Sun, C. R. Kent, K. S. Magnuson, D. G. Perregaux, P. S. Sawyer, and E. M. Kudlacz. 2008. The specificity of JAK3 kinase inhibitors. Blood 111(4):2155-2157. Chapman, S. W., W. E. Dismukes, L. A. Proia, R. W. Bradsher, P. G. Pappas, M. G. Threlkeld, and C. A. Kauffman. 2008. Clinical practice guidelines for the management of blasto- mycosis: 2008 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 46(12):1801-1812. Chaudhry, S., S. Schroter, R. Smith, and J. Morris. 2002. Does declaration of compet- ing interests affect readersâ perceptions? A randomised trial. British Medical Journal 325(7377):1391-1392. Chew, L. D., T. S. OâYoung, T. K. Hazlet, K. A. Bradley, C. Maynard, and D. S. Lessler. 2000. A physician survey of the effect of drug sample availability on physiciansâ behavior. Journal of General Internal Medicine 15(7):478-483. Chimonas, S., T. A. Brennan, and D. J. Rothman. 2007. Physicians and drug representa- tives: exploring the dynamics of the relationship. Journal of General Internal Medicine 22(2):184-190. Chiong, W. 2003. Industry-to-physician marketing and the cost of prescription drugs. Ameri- can Journal of Bioethics 3(3):W28-W29. Cho, M. K., R. Shohara, A. Schissel, and D. Rennie. 2000. Policies on faculty conflicts of interest at US universities. Journal of the American Medical Association 284(17):2203-2208. Choudhry, N. K., H. T. Stelfox, and A. S. Detsky. 2002. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association 287(5):612-617. Chren, M. M., and C. S. Landefeld. 1994. Physiciansâ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. Journal of the American Medical Association 271(9):684-689. Christie, J. D., I. M. Rosen, L. M. Bellini, T. V. Inglesby, J. Lindsay, A. Alper, and D. A. Asch. 1998. Prescription drug use and self-prescription among resident physicians. Journal of the American Medical Association 280(14):1253-1255. Citron, P. 2008. Medical device considerations. Presentation to the Institute of Medicine Com- mittee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, January 21. Clamon, J. B. 2003. The search for a cure: combating the problem of conflicts of interest that currently plagues biomedical research. Iowa Law Review 89(1):235-271. Clancy, C. M. 2003. Back to the future. Health Affairs Suppl Web Exclusives: W3-314âW3-316.
250 CONFLICT OF INTEREST CMS (Centers for Medicare and Medicaid Services). 2006. National Coverage Determinations with Data Collection as a Condition of Coverage: Coverage with Evidence Development. Baltimore, MD: CMS. http://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8 (ac- cessed October 7, 2008). CMS. 2008. Factsheet: Physician Self-Referral and Hospital Ownership Disclosure Provisions in the IPPS FY 2009 Final Rule. Baltimore, MD: CMS. http://www.Cms.Hhs.Gov/Apps/ Media/Press/Factsheet.Asp?Counter=3226&Intnumperpage=10&Checkdate=&Checkke y=&Srchtype=1&Numdays=3500&Srchopt=0&Srchdata=&Keywordtype=All&Chknew stype=6&Intpage=&Showall=&Pyear=&Year=&Desc=False&Cboorder=Date (accessed March 21, 2009). CMSS (Council of Medical Specialty Societies). 1999. Ethics Statement. Chicago, IL: CMSS. http://www.cmss.org/print.cfm?itemid=1100 (accessed November 20, 2008). CMSS. 2008. CMSS Task Force on Professionalism and Conflict of Interest in Medicine: Recommendations. Chicago, IL: CMSS. http://www.cmss.org/index.cfm?p=readmore& itemID=1358&detail=News%20Items (accessed February 26, 2009). Cochrane Collaboration. 2002. An Introduction to Meta-Analysis. Baltimore, MD: Cochrane Collaboration. http://www.cochrane-net.org/openlearning/html/mod3-2.htm (accessed March 23, 2009). Cochrane Collaboration. 2005. Glossary of Terms in the Cochrane Collaboration. Baltimore, MD: Cochrane Collaboration. http://www.cochrane.org/resources/handbook/glossary. pdf (accessed July 17, 2008). Cochrane Collaboration. 2006. Commercial Sponsorship and the Cochrane Collaboration. Baltimore, MD: Cochrane Collaboration. http://www.cochrane.org/docs/commercial- sponsorship.htm (accessed March 21, 2009). COGR (Council on Governmental Relations). 2002. Recognizing and Managing Personal Financial Conflicts of Interest. Washington, DC: COGR. http://www.cogr.edu/docs/ COIFinal.pdf (accessed September 19, 2008). COGR. 2003. Approaches to Developing an Institutional Conflict of Interest Policy. Wash- ington, DC: COGR. http://www.cogr.edu/files/publications_Conflicts.cfm (accessed November 11, 2008). Columbia College of Physicians and Surgeons. 2008. New Conflict of Interest Policy Re- garding Education and Clinical Care for P&S Faculty. New York: Columbia College of Physicians and Surgeons. http://www.columbia.edu/cu/administration/policylibrary/ policies/00bb9c661ce31c31011eda93ef3c0008/PS_COI_policy_2008_FINAL_ 1232028040523.pdf (accessed March 23, 2009). Columbia University. 2009. Columbia University Policy on Financial Conflicts of Interest and Research. New York: Columbia University. http://evpr.columbia.edu/files_sponsored projectprocedures/imce_shared/COI_Policy_4_3_09_new.pdf (accessed April 10, 2009). Columbia University. Undated. Responsible Conduct of Research: Conflicts of Interest. New York, NY: Columbia University. http://www.columbia.edu/ccnmtl/projects/rcr/rcr_ conflicts/ (accessed March 21, 2009). CONSORT Group. 2001. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 134(8):663-694. CONSORT Group. 2007. About CONSORT. http://www.consort-statement.org/?o=1014 (accessed September 26, 2008). Cook, D. M., E. A. Boyd, C. Grossmann, and L. A. Bero. 2007. Reporting science and conflicts of interest in the lay press. PLoS ONE 2(12):e1266. Cooper, D. S., G. M. Doherty, B. R. Haugen, R. T. Kloos, S. L. Lee, S. J. Mandel, E. L. Mazzaferri, et al. 2006a. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2):109-142.
REFERENCES 251 Cooper, R. J., M. Gupta, M. S. Wilkes, and J. R. Hoffman. 2006b. Conflict of interest dis- closure policies and practices in peer-reviewed biomedical journals. Journal of General Internal Medicine 21(12):1248-1252. Cosgrove, L., S. Krimsky, M. Vijayaraghavan, and L. Schneider. 2006. Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychoso- matics 75(3):154-160. Cottingham, A. H., A. L. Suchman, D. K. Litzelman, R. M. Frankel, D. L. Mossbarger, P. R. Williamson, D. C. Baldwin, Jr., and T. S. Inui. 2008. Enhancing the informal curriculum of a medical school: a case study in organizational culture change. Journal of General Internal Medicine 23(6):715-722. Council on Scientific Affairs and Council on Ethical and Judicial Affairs. 1990. Conflicts of interest in medical center/industry research relationships. Journal of the American Medi- cal Association 263(20):2790-2793. Coyle, S. L., Ethics and Human Rights Committee, and American College of Physicians- American Society of Internal Medicine. 2002a. Physician-industry relations. Part 1. Individual physicians. Annals of Internal Medicine 136(5):396-402. Coyle, S. L., Ethics and Human Rights Committee, and American College of Physicians- American Society of Internal Medicine. 2002b. Physician-industry relations. Part 2. Organizational issues. Annals of Internal Medicine 136(5):403-406. Coyne, D. W. 2007. Influence of industry on renal guideline development. Clinical Journal of the American Society of Nephrology 2(1):3-7; discussion 13-14. CTSA (Clinical and Translational Science Awards). 2009. About CTSA. http://www.ctsaweb. org/index.cfm?fuseaction=home.aboutHome (accessed March 19, 2009). Culliton, B. J. 1982. The academic-industrial complex. Science 216(4549):960-962. Curfman, G. D., S. Morrissey, and J. M. Drazen. 2005. Expression of concern: Bombardier et al., âComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,â N Engl J Med 2000;343:1520-8. New England Journal of Medicine 353(26):2813-2814. Cutrona, S. L., S. Woolhandler, K. E. Lasser, D. H. Bor, D. McCormick, and D. U. Himmelstein. 2008. Characteristics of recipients of free prescription drug samples: a nationally repre- sentative analysis. American Journal of Public Health 98(2):284-289. Dana, J., and G. Loewenstein. 2003. A social science perspective on gifts to physicians from industry. Journal of the American Medical Association 290(2):252-255. Darves, B. 2007. Physician Employment and Compensation Outlook for â07. http://www. nejmjobs.org/career-resources/physician-compensation-trends.aspx (accessed September 17, 2008). Daugherty, K. K. 2005. Samples: to use or not to use? Journal of Clinical Pharmacy and Therapeutics 30(6):505-510. Davidoff, F. 2002. Between the lines: navigating the uncharted territory of industry-sponsored research. Health Affairs 21(2):235-242. Davidoff, F., C. D. DeAngelis, J. M. Drazen, M. G. Nicholls, J. Hoey, L. Hojgaard, R. Horton, et al. 2001. Sponsorship, authorship and accountability. Canadian Medical Association Journal 165(6):786-788. Davidson, J. M., A. M. Aquino, S. C. Woodward, and W. W. Wilfinger. 1999. Sustained microgravity reduces intrinsic wound healing and growth factor responses in the rat. FASEB Journal 13(2):325-329. Davis, M. 1998. Conflict of interest. In Encyclopedia of Applied Ethics, edited by R. Chadwick. London: Academic Press. Davis, M., and A. Stark. 2001. Conflict of Interest in the Professions. New York: Oxford University Press.
252 CONFLICT OF INTEREST Dawson, D. L. 2006. Training in carotid artery stenting: do carotid simulation systems really help? Vascular 14(5):256-263. de Haas, E. R., H. C. de Vijlder, W. S. van Reesema, J. J. van Everdingen, and H. A. Neumann. 2007. Quality of clinical practice guidelines in dermatological oncology. Journal of the European Academy of Dermatology and Venereology 21(9):1193-1198. DeAngelis, C. D. 2006. The influence of money on medical science. Journal of the American Medical Association 296(8):996-998. DeAngelis, C. D., and P. B. Fontanarosa. 2008. Impugning the integrity of medical science: the adverse effects of industry influence. Journal of the American Medical Association 299(15):1833-1835. DeAngelis, C. D., P. B. Fontanarosa, and A. Flanagin. 2001. Reporting financial conflicts of interest and relationships between investigators and research sponsors. Journal of the American Medical Association 286(1):89-91. Decker, R. S., L. Wimsatt, A. G. Trice, and J. A. Konstan. 2007. A Profile of Federal-Grant ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ Administrative Burden Among Federal Demonstration Partnership Faculty. Report of the Faculty Standing Committee of the Federal Demonstration Partnership. Washington, DC: Federal Demonstration Partnership. http://www.thefdp.org/Faculty%20burden%2 0survey%20report%20-%20complete.pdf (accessed July 2, 2008). Dellinger, R. P., M. M. Levy, J. M. Carlet, J. Bion, M. M. Parker, R. Jaeschke, K. Reinhart, et al. 2008. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine 34(1):17-60. DeMaria, A. N. 2004. Authors, industry, and review articles. Journal of the American College of Cardiology 43(6):1130-1131. Demske, G. E. 2008. Examining the Relationship Between the Medical Device Industry and Physicians. Testimony before the Special Committee on Aging, U.S. Senate, February 27. http://aging.senate.gov/events/hr188gd2.pdf (accessed August 11, 2008). DeRenzo, E. G. 2005. Conflict-of-interest policy at the National Institutes of Health: the pendulum swings wildly. Kennedy Institute of Ethics Journal 15(2):199-210. Detsky, A. S. 2006. Sources of bias for authors of clinical practice guidelines. Canadian Medi- cal Association Journal 175(9):1033, 1035. Deyo, R. A., B. M. Psaty, G. Simon, E. H. Wagner, and G. S. Omenn. 1997. The messenger under attackâintimidation of researchers by special-interest groups. New England Jour- nal of Medicine 336(16):1176-1180. Dicken, P., L. J. Grant, and S. Jones. 2000. An evaluation of the characteristics and performance of neonatal phototherapy equipment. Physiological Measurement 21(4):493-503. Dickersin, K. 1990. The existence of publication bias and risk factors for its occurrence. Journal of the American Medical Association 263(10):1385-1389. Dickersin, K., S. Chan, T. C. Chalmers, H. S. Sacks, and H. Smith, Jr. 1987. Publication bias and clinical trials. Controlled Clinical Trials 8(4):343-353. Dickersin, K., Y. I. Min, and C. L. Meinert. 1992. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. Journal of the American Medical Association 267(3):374-378. Dickler, R. M. 2007. Untitled. Letter on behalf of the Association of American Medical Col- leges to Glenn Hackbarth, Chair of Medicare Payment Advisory Commission, January 4. http://www.aamc.org/advocacy/teachhosp/medpac/hackbarth_final.pdf (accessed Sep- tember 3, 2008). DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2003. The price of innovation: new esti- mates of drug development costs. Journal of Health Economics 22(2):151-185.
REFERENCES 253 DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2004. Assessing Claims About the ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ Cost of New Drug Development: A Critique of the Public Citizen and TB Alliance Re- ports. http://csdd.tufts.edu/_documents/www/Doc_231_45_735.pdf (accessed October 10, 2008). Dinan, M. A., K. P. Weinfurt, J. Y. Friedman, J. S. Allsbrook, J. Gottlieb, K. A. Schulman, M. A. Hall, J. K. Dhillon, and J. Sugarman. 2006. Comparison of conflict of interest policies and reported practices in academic medical centers in the United States. Account- ability in Research 13(4):325-342. DOJ (U.S. Department of Justice). 2001. Tap Pharmaceutical Products Inc. and Seven Oth- ers Charged with Health Care Crimes; Company Agrees to Pay $875 Million to Settle Charges. Press release, October 3. Washington, DC: DOJ. http://www.usdoj.gov/opa/ pr/2001/October/513civ.htm (accessed September 17, 2008). DOJ. 2004. Warner-Lambert to Pay $430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion. Press release, May 13. Washington, DC: DOJ. http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm (accessed September 25, 2008). DOJ. 2006. Medtronic to Pay United States $40 Million to Settle Kickback Allegations. Press release, July 18. Washington, DC: DOJ. http://www.usdoj.gov/opa/pr/2006/July/06_civ_ 445.html (accessed September 25, 2008). DOJ. 2007a. Five Companies in Hip and Knee Replacement Industry Avoid Prosecution by Agreeing to Compliance Rules and Monitoring. Press release, September 27. Washington, DC: DOJ. http://www.usdoj.gov/usao/nj/press/files/pdffiles/hips0927.rel.pdf (accessed July 28, 2008). DOJ. 2007b. Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in âOff-Labelâ Marketing Investigation. Press release, July 13. Wash- ington, DC: DOJ. http://www.usdoj.gov/usao/nye/pr/2007/2007jul13a.html (accessed September 25, 2008). DOJ. 2008. Merck to Pay More Than $650 Million to Resolve Claims of Fraudulent Price Reporting and Kickbacks. Press release, February 7. Washington, DC: DOJ. http://www. usdoj.gov/opa/pr/2008/February/08_civ_094.html (accessed September 17, 2008). Drazen, J. M., and G. D. Curfman. 2002. Financial associations of authors. New England Journal of Medicine 346(24):1901-1902. Druker, B. J., F. Guilhot, S. G. OâBrien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W. Deininger, et al. 2006. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine 355(23):2408-2417. Duderstadt, J. J. 2000. A University for the 21st Century. Ann Arbor: University of Michigan Press. Duffy, S. P. 2003. Pharmaceutical companies to pay $1.2B in Medicare fraud. The Legal Intelligencer, June 24. http://www.law.com/jsp/article.jsp?id=1056139882090 (accessed August 11, 2008). Duvall, D. G. 2006. Conflict of interest or ideological divide: the need for ongoing col- laboration between physicians and industry. Current Medical Research and Opinion 22(9):1807-1812. Easterbrook, P. J., J. A. Berlin, R. Gopalan, and D. R. Matthews. 1991. Publication bias in clinical research. Lancet 337(8746):867-872. Eaton, L. 2005. Medical editors issue guidance on ghost writing. British Medical Journal 330(7498):988. EBM Working Group. 1992. Evidence-based medicine. A new approach to teaching the prac- tice of medicine. Journal of the American Medical Association 268(17):2420-2425.
254 CONFLICT OF INTEREST ECRI Institute. 2007. Sales representatives and other outsiders in the OR. Operating Room Risk Management, November, vol. 2. Plymouth Meeting, PA: ECRI Institute. https:// www.ecri.org/Documents/Sample_ORRM_Outsiders_in_the_OR_Report.pdf (accessed December 30, 2008). Editors. 2007. Probing STROBE. Epidemiology 18(6):789-790. Edwards, J. C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. Close, R. M. Stevens, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine 350(25):2572-2581. EHP (Environmental Health Perspectives). 2009. Instructions to authors. Environmental Health Perspectives 115(7):366-371. http://www.ehponline.org/docs/admin/instructions. pdf (accessed August 12, 2008). Ehringhaus, S., and D. Korn. 2004. U.S. Medical School Policies on Individual Financial Conflicts of Interest: Results of an AAMC Survey. Washington, DC: Association of American Medical Colleges. http://www.aamc.org/research/coi/coiresults2003.pdf (ac- cessed October 21, 2008). Ehringhaus, S., and D. Korn. 2006. Principles for Protecting Integrity in the Conduct and Reporting of Clinical Trials. Washington, DC: Association of American Medical Colleges. http://www.aamc.org/research/clinicaltrialsreporting/clinicaltrialsreporting.pdf (accessed October 22, 2008). Ehringhaus, S., J. S. Weissman, J. L. Sears, S. D. Goold, S. Feibelmann, and E. G. Campbell. 2008. Responses of medical schools to institutional conflicts of interest. Journal of the American Medical Association 299(6):665-671. Eichacker, P. Q., C. Natanson, and R. L. Danner. 2006. Surviving sepsisâpractice guide- ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ lines, marketing campaigns, and Eli Lilly. New England Journal of Medicine 355(16): 1640-1642. Eichacker, P. Q., C. Natanson, and R. L. Danner. 2007. Separating practice guidelines from pharmaceutical marketing. Critical Care Medicine 35(12):2877-2878; author reply 2878-2880. Eisenberg, J. M., and D. Zarin. 2002. Health technology assessment in the United States. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ Past, present, and future. International Journal of Technology Assessment in Health Care 18(2):192-198. Elliott, C. 2004. Pharma goes to the laundry: public relations and the business of medical education. Hastings Center Report 34(5):18-23. Elliott, C. 2006. The drug pushers. Atlantic Magazine, April. http://www.theatlantic.com/ doc/200604/drug-reps/3 (accessed November 21, 2008). Emanuel, E., and D. Steiner. 1995. Institutional conflict of interest. New England Journal of Medicine 332(4):262-267. Emanuel, E., and D. F. Thompson. 2008. The concept of conflicts of interest. In The Oxford Textbook of Clinical Research Ethics, edited by E. Emanuel, C. Grady, R. Crouch, R. Lie, F. Miller, and D. Wendler. New York: Oxford University Press. EPIC Investigators. 1994. Use of a monoclonal antibody directed against the platelet glyco- protein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New England Journal of Medicine 330(14):956-961. Epstein, A. M. 2007a. Pay for performance at the tipping point. New England Journal of Medicine 356(5):515-517. Epstein, A. M., T. H. Lee, and M. B. Hamel. 2004. Paying physicians for high-quality care. New England Journal of Medicine 350(4):406-410. Epstein, R. A. 2005. Pharma furor: why two high-profile attacks on big drug companies flunk the test of basic economics. Legal Affairs Magazine, January/February. http://www. legalaffairs.org/issues/January-February-2005/review_epstein_janfeb05.msp (accessed September 15, 2008).
REFERENCES 255 Epstein, R. A. 2007b. Conflicts of interest in health care: who guards the guardians? Perspec- tives in Biology and Medicine 50(1):72-88. Erde, E. L. 1996. Conflicts of interests in medicine: a philosophical and ethical morphology. In Conflicts of Interest in Clinical Practice and Research, edited by R. G. Spece, D. S. Shimm, and A. E. Buchanan. New York: Oxford University Press Ethics, Law, and Humanities Committee of the American Academy of Neurology. 2001. Prac- tice advisory: participation of neurologists in direct-to-consumer advertising. Neurology 56(8):995-996. Fahrenthold, D. A. 2006. U.S. criminal charges filed against scientist; undisclosed consulting deals at issue. The Washington Post, December 5, B06. Fallat, M. E., and J. Glover. 2007. Professionalism in pediatrics. Pediatrics 120(4): e1123-e1133. Farrell, R. J., Y. Ang, P. Kileen, D. S. OâBriain, D. Kelleher, P. W. Keeling, and D. G. Weir. 2000. Increased incidence of non-Hodgkinâs lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47(4):514-519. FASEB (Federation of American Societies for Experimental Biology). 2008. COI Toolkit: Recommendations, Tools, and Resources for the Conduct and Management of Finan- cial Relationships Between Academia and Industry in Biomedical Research. Bethesda, MD: FASEB. http://opa.faseb.org/pages/Advocacy/coi/Toolkit.htm (accessed March 21, 2009). FDA (U.S. Food and Drug Administration). 1995. Confidential Financial Disclosure Report for Special Government Employees. Silver Spring, MD: FDA. http://www.fda.gov/oc/ advisory/conflictofinterest/disclosure.pdf (accessed July 3, 2008). FDA. 1997. Guidance for industry: industry-supported scientific and educational activities. Federal Register 62(232):64093-64100. FDA. 2000. FDA Guidance on Conflict of Interest for Advisory Committee Members, Con- sultants and ExpertsâTable of Contents. Silver Spring, MD: FDA. http://www.fda. gov/oc/advisory/conflictofinterest/guidance.html (accessed July 3, 2008). FDA. 2001. Guidance: Financial Disclosure by Clinical Investigators. Silver Spring, MD: FDA. http://www.fda.gov/oc/guidance/financialdis.html (accessed February 2, 2009). FDA. 2004a. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Washington, DC: U.S. Department of Health and Human Ser- vices. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (accessed February 18, 2009). FDA. 2004b. RE: P040012 ACCULINK Carotid Stent System and RX ACCULINK Carotid Stent System. Letter from Dr. Tillman, Center for Devices and Radiological Health, to Ms. Anastas, Guidant Corporation, August 30. http://www.fda.gov/cdrh/pdf4/P040012a. pdf (accessed October 7, 2008). FDA. 2008a. Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Membersâ Financial Interest Information and Waivers. Silver Spring, MD: FDA. http://www.fda.gov/oc/advisory/GuidancePolicyRegs/ ACDisclosureFINALGuidance080408.pdf (accessed August 18, 2008). FDA. 2008b. Guidance for the Public, FDA Advisory Committee Members, and FDA Staff on Procedures for Determining Conflict of Interest and Eligibility for Participation in FDA Advisory Committees. Silver Spring, MD: FDA. http://www.fda.gov/oc/advisory/ GuidancePolicyRegs/ACWaiverCriteriaFINALGuidance080408.pdf (accessed August 12, 2008). Finance Committee, U.S. Senate. 2007. Use of Educational Grants by Pharmaceutical Manu- facturers. Washington, DC: U.S. Government Printing Office. http://www.acme-assn. org/home/prb042507a.pdf (accessed November 21, 2008).
256 CONFLICT OF INTEREST Finance Committee, U.S. Senate. 2008. Support for S.2029, the Grassley-Kohl Physician Pay- ments Sunshine Act. Washington, DC: U.S. Government Printing Office. http://finance. senate.gov/press/Gpress/2008/prg071608a.pdf (accessed August 12, 2008). Fink, A., J. Kosecoff, M. Chassin, and R. H. Brook. 1984. Consensus methods: characteristics and guidelines for use. American Journal of Public Health 74(9):979-983. Finkelstein, S. N., K. A. Isaacson, and J. J. Frishkopf. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 1984. The process of evaluating medical technologies for third-party coverage. Journal of Health Care Technology 1(2):89-102. Finn, P. B. 2006. The negotiation and development of a clinical trial agreement. Journal of Biolaw & Business 9(2):21-27. Fitch, K., P. Lazaro, M. D. Aguilar, Y. Martin, and S. J. Bernstein. 1999. Physician recom- mendations for coronary revascularization: variations by clinical specialty. The European Journal of Public Health 9(3):181-187. Fitz, M. M., D. Homan, S. Reddy, C. H. Griffith III, E. Baker, and K. P. Simpson. 2007. The hidden curriculum: medical studentsâ changing opinions toward the pharmaceutical industry. Academic Medicine 82(10 Suppl.):S1-S3. Flanagin, A., L. A. Carey, P. B. Fontanarosa, S. G. Phillips, B. P. Pace, G. D. Lundberg, and D. Rennie. 1998. Prevalence of articles with honorary authors and ghost au- thors in peer-reviewed medical journals. Journal of the American Medical Association 280(3):222-224. Flanagin, A., P. B. Fontanarosa, and C. D. DeAngelis. 2006. Update on JAMAâs conflict of interest policy. Journal of the American Medical Association 296(2):220-221. Fletcher, S. W. 2008. Chairmanâs summary of the conference. In Continuing Education in the Health Professions: Improving Healthcare Through Lifelong Learning, edited by M. Hager. New York: Josiah Macy, Jr., Foundation. Flewell, M. N. 2007. A look ahead . . . oncology sales force effectiveness in an era of unprecedented competition. Oncology Business Review, June. http://www.oncbiz.com/ documents/OBRjune07_ImpactRX.pdf (accessed August 27, 2007). Fontanarosa, P. B., and C. D. DeAngelis. 2008. Publication of clinical trials in JAMA. Journal ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ of the American Medical Association 299(1):95-96. Fontanarosa, P. B., A. Flanagin, and C. D. DeAngelis. 2005. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. Journal of the American Medical Association 294(1):110-111. Frankel, M. S. 1996. Perception, reality, and the political context of conflict of interest in university-industry relationships. Academic Medicine 71(12):1297-1304. Friedman, P. J. 1992. The troublesome semantics of conflict of interest. Ethics & Behavior 2(4):245-251. Frohlich, E. P. 2007. The high cost of free lunch. Obstetrics and Gynecology 110(4):931; author reply 932-933. Fugh-Berman, A. 2005. The corporate coauthor. Journal of General Internal Medicine 20(6): 546-548. Fugh-Berman, A., and S. Ahari. 2007. Following the script: how drug reps make friends and influence doctors. PLoS Medicine 4(4):e150. Fugh-Berman, A., and S. Batt. 2006. This may sting a bit. Virtual Mentor 8(6):412-415. http:// virtualmentor.ama-assn.org/2006/06/oped1-0606.html (accessed October 10, 2008). Fung, A., M. Graham, and D. Weil. 2007. Full Disclosure: The Perils and Promise of Trans- parency. New York, NY: Cambridge University Press. Gagnon, M. A., and J. Lexchin. 2008. The cost of pushing pills: a new estimate of pharma- ceutical promotion expenditures in the United States. PLoS Medicine 5(1):e1.
REFERENCES 257 GAO (U.S. General Accounting Office [Now the U.S. Government Accountability Office]). 1995. Increased HMO Oversight Could Improve Quality and Access to Care. Report to the Special Committee on Aging, U.S. Senate. Washington, DC: GAO. http://www.gao. gov/archive/1995/he95155.pdf (accessed February 10, 2009). GAO. 2001. HHS Direction Needed to Address Financial Conflicts of Interest. Report to the Ranking Minority Member, Subcommittee on Public Health, Committee on Health, Education, Labor, and Pensions, U.S. Senate. Washington, DC: GAO. http://www.gao. gov/new.items/d0289.pdf (accessed February 10, 2009). GAO. 2003. Most Federal Agencies Need to Better Protect Against Financial Conflicts of In- terest. Report to the Honorable Richard C. Shelby, U.S. Senate. Washington, DC: GAO. http://www.gao.gov/new.items/d0431.pdf (accessed August 1, 2008). Garb, S. 1960. Teaching medical students to evaluate drug advertising. Journal of Medical Education 35:729-739. Garber, A. M. 2001. Evidence-based coverage policy. Health Affairs 20(5):62-82. Gaus, C. R. 2003. An insiderâs perspective on the near-death experience of AHCPR. Health Affairs Suppl Web Exclusives:W3-311âW3-313. Gelijns, A. C., and S. O. Thier. 2002. Medical innovation and institutional interdependence: rethinking university-industry connections. Journal of the American Medical Association 287(1):72-77. Geppert, C. M. 2007. Medical education and the pharmaceutical industry: a review of ethical guidelines and their implications for psychiatric training. Academic Psychiatry 31(1):32-39. Gibbons, R. V., F. J. Landry, D. L. Blouch, D. L. Jones, F. K. Williams, C. R. Lucey, and K. Kroenke. 1998. A comparison of physiciansâ and patientsâ attitudes toward pharmaceuti- cal industry gifts. Journal of General Internal Medicine 13(3):151-154. Gibson, L. 2004. GlaxoSmithKline to publish clinical trials after US lawsuit. British Medical Journal 328(7455):1513. Gilbert, S. 2008. The invisible hand in medical education. Bioethics Forum, March 14. http:// www.thehastingscenter.org/bioethicsforum/post.aspx?id=736&terms=the+invisible +hand+and+%23filename+*.html (accessed October 10, 2008). Ginsburg, P. B., and J. M. Grossman. 2005. When the price isnât right: how inadvertent payment incentives drive medical care. Health Affairs Suppl Web Exclusives:W5-376âW5-384. Ginzberg, E., and A. Dutka. 1989. The Financing of Biomedical Research. Baltimore, MD: The Johns Hopkins University Press. Glaser, B. E., and L. A. Bero. 2005. Attitudes of academic and clinical researchers to- ward financial ties in research: a systematic review. Science and Engineering Ethics 11(4):553-573. Goldblum, O. M., and M. J. Franzblau. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2006. Academic medical centers and conflicts of interest. Journal of the American Medical Association 295(24):2845-2846; author reply 2848-2849. Golden, G. A., J. N. Parochka, and K. M. Overstreet. 2002. Medical education and commu- nication companies: an updated in-depth profile. Journal of Continuing Education in the Health Professions 22(1):55-62. Golder, S., and Y. K. Loke. 2008. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? British Journal of Clinical Phar- macology 66(6):767-773. Goldner, J. A. 2000. Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach. Journal of Law, Medicine and Ethics 28(4):379-404. Goldsmith, L. A. 2006. Conflict of interest and the JID. Journal of Investigative Dermatology 126:2147-2148.
258 CONFLICT OF INTEREST Goldstein, J. 2008. Implant firms pay doctors millions; as joint replacements have increased, so have payments to surgeons. The Philadelphia Inquirer, June 29, A01. Goldstein, N. 2006. Financial conflicts of interest in biomedical human subject research. Journal of Biolaw & Business 9(1):26-37. Goozner, M. 2004. Unrevealed: Non-Disclosure of Conflicts of Interest in Four Leading Medi- cal and Scientific Journals. Washington, DC: Center for Science in the Public Interest. http://cspinet.org/new/pdf/unrevealed_final.pdf (accessed November 11, 2008). Goroll, A. H., R. A. Berenson, S. C. Schoenbaum, and L. B. Gardner. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2007. Fundamental reform of payment for adult primary care: comprehensive payment for comprehensive care. Journal of General Internal Medicine 22(3):410-415. Gott, V. L., D. E. Alejo, and D. E. Cameron. 2003. Mechanical heart valves: 50 years of evolu- tion. Annals of Thoracic Surgery 76(6):S2230-S2239. Gotzsche, P. C., A. Hrobjartsson, H. K. Johansen, M. T. Haahr, D. G. Altman, and A. W. Chan. 2006. Constraints on publication rights in industry-initiated clinical trials. Journal of the American Medical Association 295(14):1645-1646. Gotzsche, P. C., A. Hrobjartsson, H. K. Johansen, M. T. Haahr, D. G. Altman, and A. W. Chan. 2007. Ghost authorship in industry-initiated randomised trials. PLoS Medicine 4(1):e19. Gourley, R. H. 1966. Teaching the evaluation of drug advertising to medical students. Virginia Medical Monthly (1918) 93(8):459-461. GRADE Working Group. 2004. Grading quality of evidence and strength of recommenda- tions. British Medical Journal 328(7454):1490. Grassley, C. 2008a. Grassley Works to Protect Medicare Dollars, Empower Patients with Information. Press release, July 25. http://www.senate.gov/~finance/press/Gpress/2008/ prg072508.pdf (accessed September 17, 2008). Grassley, C. 2008b. Payment to physicians. Congressional RecordâSenate, p. S5030. http:// frwebgate.access.gpo.gov/cgi-bin/getpage.cgi?dbname=2008_record&page=S5030&posi tion=all (accessed July 17, 2008). Grassley, C. 2009. Grassley Works to Disclose Financial Ties Between Drug Companies and Doctors. Press release, January 22. http://grassley.senate.gov/news/Article.cfm?customel_ dataPageID_1502=18901 (accessed February 26, 2009). Gray, B. H., M. K. Gusmano, and S. R. Collins. 2003. AHCPR and the changing politics of health services research. Health Affairs Suppl Web Exclusives:W3-283âW3-307. Gray, S. W., F. J. Hlubocky, M. J. Ratain, and C. K. Daugherty. 2007. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients par- ticipating in early phase clinical trials. Journal of Clinical Oncology 25(23):3488-3494. Greene, J. A. 2007. Pharmaceutical marketing research and the prescribing physician. Annals of Internal Medicine 146(10):742-748. Grilli, R., N. Magrini, A. Penna, G. Mura, and A. Liberati. 2000. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 355(9198):103-106. Grimshaw, J. M., and I. T. Russell. 1993. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 342(8883):1317-1322. Grimshaw, J. M., L. Shirran, R. Thomas, G. Mowatt, C. Fraser, L. Bero, R. Grilli, et al. 2001. Changing provider behavior: an overview of systematic reviews of interventions. Medical Care 39(8 Suppl. 2):II2-II45. Grimshaw, J. M., M. Eccles, R. Thomas, G. MacLennan, C. Ramsay, C. Fraser, and L. Vale. 2006. Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966-1998. Journal of General Internal Medicine 21(Suppl. 2):S14-S20.
REFERENCES 259 Gross, C. P. 2007. Conflict of interest and clinical research. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Prac- tice, Washington, DC, November 6. Gross, C. P., A. R. Gupta, and H. M. Krumholz. 2003. Disclosure of financial competing interests in randomised controlled trials: cross sectional review. British Medical Journal 326(7388):526-527. Groves, K. E., I. Sketris, and S. E. Tett. 2003. Prescription drug samplesâdoes this marketing strategy counteract policies for quality use of medicines? Journal of Clinical Pharmacy and Therapeutics 28(4):259-271. Guirguis-Blake, J., N. Calonge, T. Miller, A. Siu, S. Teutsch, and E. Whitlock. 2007. Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommen- dation development. Annals of Internal Medicine 147(2):117-122. Guyatt, G. H., and D. Rennie. 2002. Usersâ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: American Medical Association. Guyatt, G. H., D. L. Sackett, J. C. Sinclair, R. Hayward, D. J. Cook, and R. J. Cook. 1995. Usersâ guides to the medical literature. IX. A method for grading health care recommen- dations. Evidence-Based Medicine Working Group. Journal of the American Medical Association 274(22):1800-1804. Guyatt, G. H., G. Vist, Y. Falck-Ytter, R. Kunz, N. Magrini, and H. Schunemann. 2006. An emerging consensus on grading recommendations? ACP Journal Club 144(1):A8-A9. Guyatt, G. H., A. D. Oxman, R. Kunz, G. E. Vist, Y. Falck-Ytter, and H. J. Schunemann. 2008. What is âquality of evidenceâ and why is it important to clinicians? British Medi- cal Journal 336(7651):995-998. Hafferty, F. W. 1998. Beyond curriculum reform: confronting medicineâs hidden curriculum. Academic Medicine 73(4):403-407. Haidet, P. 2008. Where weâre headed: a new wave of scholarship on educating medical profes- sionalism. Journal of General Internal Medicine 23(7):1118-1119. Haivas, I., S. Schroter, F. Waechter, and R. Smith. 2004. Editorsâ declaration of their own conflicts of interest. Canadian Medical Association Journal 171(5):475-476. Hall, M. A., E. Dugan, R. Balkrishnan, and D. Bradley. 2002. How disclosing HMO physician incentives affects trust. Health Affairs 21(2):197-206. Halperin, E. C., P. Hutchison, and R. C. Barrier, Jr. 2004. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. International Journal of Radiation Oncology, Biology, Physics 59(5):1477-1483. Hampson, L. A., M. Agrawal, S. Joffe, C. P. Gross, J. Verter, and E. J. Emanuel. 2006. Patientsâ views on financial conflicts of interest in cancer research trials. New England Journal of Medicine 355(22):2330-2337. Hampson, L. A., J. E. Bekelman, and C. Gross. 2008. Empirical data on conflicts of interest. In The Oxford Textbook of Clinical Research Ethics, edited by E. Emanuel, C. Grady, R. A. Crouch, R. K. Lie, F. G. Miller, and D. Wendler. New York: Oxford University Press. Hardell, L., M. J. Walker, B. Walhjalt, L. S. Friedman, and E. D. Richter. 2007. Secret ties to industry and conflicting interests in cancer research. American Journal of Industrial Medicine 50(3):227-233. Harpole, L. H., M. J. Kelley, G. Schreiber, E. M. Toloza, J. Kolimaga, and D. C. McCrory. 2003. Assessment of the scope and quality of clinical practice guidelines in lung cancer. Chest 123(1 Suppl.):7S-20S. Harris, G. 2005. Ban on federal scientistsâ consulting nears. The New York Times, February 1, A15. Harris, G. 2008. Top psychiatrist didnât report drug makersâ pay. The New York Times, October 4, A1.
260 CONFLICT OF INTEREST Harris, G., and B. Carey. 2008. Researchers fail to reveal full drug pay. The New York Times, June 8, A1. The Harvard Crimson. 1988. Interesting conflicts: medical school. http://www.thecrimson. com/article.aspx?ref=144875 (accessed July 28, 2008). Hasenfeld, R., and P. G. Shekelle. 2003. Is the methodological quality of guidelines declining in the US? Comparison of the quality of US Agency for Health Care Policy and Research (AHCPR) guidelines with those published subsequently. Quality and Safety in Health Care 12(6):428-434. Hauser, R. G., and B. J. Maron. 2005. Lessons from the failure and recall of an implantable cardioverter-defibrillator. Circulation 112(13):2040-2042. Hauser, S. L., E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine 358(7):676-688. Healy, D. 2006. Did regulators fail over selective serotonin reuptake inhibitors? British Medi- cal Journal 333(7558):92-95. Healy, D., and D. Cattell. 2003. Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry 183:22-27. Hemminki, E. 1980. Study of information submitted by drug companies to licensing authori- ties. British Medical Journal 280(6217):833-836. Henderson, J. A., and J. J. Smith. 2003. Financial conflict of interest in medical re- search: overview and analysis of institutional controls. Food and Drug Law Journal 58(2):251-267. Henry Ford Health System. 2007. Vendor Policy and Procedures. Detroit, MI: Henry Ford Health System. http://www.henryford.com/documents/Purchasing/Vendor%20Visitation %20Policyfinal0108.pdf (accessed February 10, 2009). Henschke, C. I., and D. F. Yankelevitz. 2008. Unreported financial disclosures. Journal of the American Medical Association 299(15):1770; discussion 1771. Hensley, S. 2005. To sell their drugs, companies increasingly rely on doctors. Wall Street Journal, July 15, A5. Hensley, S., and B. Martinez. 2005. To sell their drugs, companies increasingly rely on doctors. Wall Street Journal, July 15, A1, A2. Heres, S., J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht. 2006. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsy- chotics. American Journal of Psychiatry 163(2):185-194. Herrin, J., J. A. Etchason, J. P. Kahan, R. H. Brook, and D. J. Ballard. 1997. Effect of panel composition on physician ratings of appropriateness of abdominal aortic aneurysm sur- gery: elucidating differences between multispecialty panel results and specialty society recommendations. Health Policy 42(1):67-81. HHS (U.S. Department of Health and Human Services). 2004. Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protec- tion. Washington, DC: DHHS. http://www.hhs.gov/ohrp/humansubjects/finreltn/fguid. pdf (accessed July 16, 2008). HHS. 2005. Supplemental standards of ethical conduct and financial disclosure requirements for employees of the Department of Health and Human Services. Federal Register 70(168):51559- 51574. http://www.nih.gov/about/ethics/08252005supplementalfinancialdisclosure.pdf (accessed February 2, 2009). HHS. 2008. Physician Self-Referral and Hospital Ownership Disclosure Provisions in the IPPS FY 2009 Final Rule. Press release, August 4. Washington, DC: DHHS. http://www.cms. hhs.gov/apps/media/fact_sheets.asp (accessed September 16, 2008).
REFERENCES 261 Higgins, J. P., and S. Green, eds. 2008. Cochrane Handbook for Systematic Reviews of In- terventions, Version 5.0.1. Baltimore, MD: The Cochrane Collaboration. http://www. cochrane-handbook.org/ (accessed February 23, 2009) Hill, K. P., J. S. Ross, D. S. Egilman, and H. M. Krumholz. 2008. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine 149(4):251-258. Hillman, A. L. 1987. Financial incentives for physicians in HMOs. Is there a conflict of inter- est? New England Journal of Medicine 317(27):1743-1748. Hillman, B. J., C. A. Joseph, M. R. Mabry, J. H. Sunshine, S. D. Kennedy, and M. Noether. 1990. Frequency and costs of diagnostic imaging in office practiceâa comparison of self-referring and radiologist-referring physicians. New England Journal of Medicine 323(23):1604-1608. The House of Commons Health Committee (United Kingdom). 2005. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004â05. London: House of Commons. http://www.parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/ cmhealth/42/42.pdf (accessed October 9, 2008). Hrachovec, J. B., and M. Mora. 2001. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. Journal of the American Medical Association 286(19):2398; author reply 2399-2400. Hsiao, W. C., D. L. Dunn, and D. K. Verrilli. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 1993. Assessing the implementation of physician- payment reform. New England Journal of Medicine 328(13):928-933. Huddle, T. S. 2008. Drug reps and the academic medical center: a case for management rather than prohibition. Perspectives in Biology and Medicine 51(2):251-260. Hurdowar, A., I. D. Graham, M. Bayley, M. Harrison, S. Wood-Dauphinee, and S. Bhogal. 2007. Quality of stroke rehabilitation clinical practice guidelines. Journal of Evaluation in Clinical Practice 13(4):657-664. Huth, E. J., and K. Case. 2004. The URM: twenty-five years old. Science Editor 27:17-21. Hyman, P. L., M. E. Hochman, J. G. Shaw, and M. A. Steinman. 2007. Attitudes of preclini- cal and clinical medical students toward interactions with the pharmaceutical industry. Academic Medicine 82(1):94-99. ICMJE (International Committee of Medical Journal Editors). 2008. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. http://www.icmje.org/icmje.pdf (accessed December 31, 2008). Ingelfinger, J. R. 2007. Through the looking glass: anemia guidelines, vested interests, and distortions. Clinical Journal of the American Society of Nephrology 2(3):415-417. IOM (Institute of Medicine). 1985. Assessing Medical Technologies. Washington, DC: Na- tional Academy Press. IOM. 1988. Medical Technology Assessment Directory: A Pilot Reference to Organizations, Assessments, and Information Resources. Washington, DC: National Academy Press. IOM. 1990. Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academy Press. IOM. 1991. Patient Outcomes Research Teams: Managing Conflict of Interest. Washington, DC: National Academy Press. IOM. 1992. Guidelines for Clinical Practice: From Development to Use. Washington, DC: National Academy Press. IOM. 1995. Setting Priorities for Clinical Practice Guidelines. Washington, DC: National Academy Press. IOM. 2001. Preserving Public Trust: Accreditation and Human Research Participant Protec- tion Programs. Washington, DC: National Academy Press. IOM. 2003. Responsible Research: A Systems Approach to Protecting Research Participants. Washington, DC: The National Academies Press.
262 CONFLICT OF INTEREST IOM. 2004. The Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press. IOM. 2006. Rewarding Provider Performance: Aligning Incentives in Medicare. Washington, DC: The National Academies Press. IOM. 2007. Learning What Works Best: The Nationâs Need for Evidence on Comparative Effectiveness in Health Care. Washington, DC: The National Academies Press. IOM. 2008. Knowing What Works in Health Care: A Roadmap for the Nation. Washington, DC: The National Academies Press. IOM. 2009. Projects: Committee on Planning a Continuing Health Care Professional Ed- ucation Institute. http://www.iom.edu/CMS/3809/59584.aspx (accessed February 18, 2009). IOM/NRC (National Research Council). 2002. Integrity in Scientific Research: Creating an Environment That Promotes Responsible Conduct. Washington, DC: The National Academies Press. Ivanis, A., D. Hren, D. Sambunjak, M. MarusiÄ, and A. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2008. Quantification of au- MarusiÄ. thorsâ contributions and eligibility for authorship: randomized study in a general medical journal. Journal of General Internal Medicine 23(9):1303-1310. Jacobs, J. J., J. O. Galante, S. K. Mirza, and T. Zdeblick. 2006. Relationships with industry: critical for new technology or an unnecessary evil? Journal of Bone and Joint Surgery 88(7):1650-1663. Jansen, L. A., and D. P. Sulmasy. 2003. Bioethics, conflicts of interest, & the limits of transpar- ency. Hastings Center Report 33(4):40-43. Jeffrey, K. 2001. Machines in Our Hearts: The Cardiac Pacemaker, the Implantable Defibrilla- tor, and American Health Care. Baltimore, MD: The Johns Hopkins University Press. Johns, M. M., M. Barnes, and P. S. Florencio. 2003. Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest: promoting research while maintaining trust. Journal of the American Medical Association 289(6):741-746. Johns Hopkins University School of Medicine. 2009. Johns Hopkins Medicine Policy on Interaction with Industry. http://www.hopkinsmedicine.org/Research/OPC/JHM industryinteractionpolicyFINAL.pdf (accessed April 10, 2009). Johnson, J. A. 1982. Biotechnology: Commercialization of Academic Research. Congressio- nal Research Service Report, Issue IB81160. Washington, DC: Congressional Research Service. http://digital.library.unt.edu/govdocs/crs/permalink/meta-crs-8589:1 (accessed August 1, 2008). Jolly, P. 2007. Medical School Tuition and Young Physician Indebtedness: An Update to the 2004 Report. Washington, DC: Association of American Medical Colleges. http://www. brynmawr.edu/healthpro/documents/AAMC_2004Med_Debt_Report.pdf (accessed Au- gust 12, 2008). Jordan, K. A. 2003. Financial conflicts of interest in human subjects research: proposals for a more effective regulatory scheme. Washington and Lee Law Review 60(1):15-109. Jorgensen, A. W., J. Hilden, and P. C. Gotzsche. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2006. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. British Medical Journal 333(7572):782-785. Jost, T. S. 2009. Oversight of marketing relationships between physicians and the drug and device industry: a comparative study. ï¿½ï¿½ï¿½ Medizin und Haftung, Festschrift fÃ¼r Erwin In Deutsch zum 80, edited by H. Ahrens, C. vonBar, G. Fischer, A. Spickhoff, and J. Taupitz. Berlin: Springer-Verlag. Kahan, J. P., R. E. Park, L. L. Leape, S. J. Bernstein, L. H. Hilborne, L. Parker, C. J. Kamberg, et al. 1996. Variations by specialty in physician ratings of the appropriateness and neces- ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ sity of indications for procedures. Medical Care 34(6):512-523.
REFERENCES 263 Kahn, J. O., D. W. Cherng, K. Mayer, H. Murray, and S. Lagakos. 2000. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV hav- ing 300 to 549 Ã 106/L CD4 cell counts: a randomized controlled trial. Journal of the American Medical Association 284(17):2193-2202. Kaiser, J. 2008. NIH suspends grant to Emory University. ScienceNOW Daily News, October 14. http://sciencenow.sciencemag.org/cgi/content/full/2008/1014/1 (accessed February 19, 2009). Kaiser Permanente/TPMG (The Permanente Medical Group). 2004. TPMG Policy Manual: Conflict of Interest Policy. http://www.sccgov.org/SCC/docs/SCC%20Public%20Portal/ keyboard%20agenda/Committee%20Agenda/2007/April%2011,%202007/TMP Keyboard201889142.pdf (accessed February 10, 2009). Kane, G. M. 2008. Conference Proceedings. Mayo CME Consensus Conference, Rochester, MN, September 25-26. Rochester, MN: Mayo Clinic. http://www.sacme.org/site/sacme/ assets/pdf/Mayo_CME_Consensus_Conf_Proceedings_1-20-09.pdf (accessed February 27, 2009). Kao, A. C., A. M. Zaslavsky, D. C. Green, J. P. Koplan, and P. D. Cleary. 2001. Physician incentives and disclosure of payment methods to patients. Journal of General Internal Medicine 16(3):181-188. Kassirer, J. P. 2001. Financial conflict of interest: an unresolved ethical frontier. American Journal of Law and Medicine 27(2-3):149-162. Kassirer, J. P. 2004. On the Take: How Medicineâs Complicity with Big Business Can Endanger Your Health. New York, NY: Oxford University Press. Kastelein, J. J., F. Akdim, E. S. Stroes, A. H. Zwinderman, M. L. Bots, A. F. Stalenhoef, F. L. Visseren, et al. 2008. Simvastatin with or without ezetimibe in familial hypercholester- olemia. New England Journal of Medicine 358(14):1431-1443. Katz, H. P., S. E. Goldfinger, and S. W. Fletcher. 2002. Academia-industry collaboration in continuing medical education: description of two approaches. Journal of Continuing Education in the Health Professions 22(1):43-54. Kaushansky, K. 2008. Untitled. Presentation for the American Society of Hematology to the Institute of Medicine Committee on Conflicts of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. KDOQI (Kidney Disease Outcomes Quality Initiative). 2007. KDOQI Clinical Practice Guide- line and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. American Journal of Kidney Diseases 50(3):471-530. Keefe, D. M., M. M. Schubert, L. S. Elting, S. T. Sonis, J. B. Epstein, J. E. Raber-Durlacher, C. A. Migliorati, D. B. McGuire, R. D. Hutchins, and D. E. Peterson. 2007. Up- dated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820-831. Keim, S. M., M. Z. Mays, and D. Grant. 2004. Interactions between emergency medicine pro- grams and the pharmaceutical industry. Academic Emergency Medicine 11(1):19-26. Keiper, A. 2005. Science and Congress. The New Atlantis Fall 2004/Winter 2005(7):19-50. Kennedy, T. C., A. McWilliams, E. Edell, T. Sutedja, G. Downie, R. Yung, A. Gazdar, et al. 2007. Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP evi- dence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl.):221S-233S. Keszler, M., and D. J. Durand. 2001. Neonatal high-frequency ventilation. Past, present, and future. Clinics in Perinatology 28(3):579-607. KFF (Kaiser Family Foundation). 2002. National Survey of Physicians part II: Doctors and Prescription Drugs. Menlo Park, CA: KFF. http://www.kff.org/rxdrugs/loader.cfm?url=/ commonspot/security/getfile.cfm&PageID=13965 (accessed August 12, 2008).
264 CONFLICT OF INTEREST Kim, S. Y., R. W. Millard, P. Nisbet, C. Cox, and E. D. Caine. 2004. Potential research partici- pantsâ views regarding researcher and institutional financial conflicts of interest. Journal of Medical Ethics 30(1):73-79. King-Casas, B., D. Tomlin, C. Anen, C. F. Camerer, S. R. Quartz, and P. R. Montague. 2005. Getting to know you: reputation and trust in a two-person economic exchange. Science 308(5718):78-83. Klanica, K. 2005. Conflicts of interest in medical research: how much conflict should exceed legal boundaries? Journal of Biolaw & Business 8(3):37-45. Klein, J. E., and A. R. Fleischman. 2002. The private practicing physician-investigator: ethical implications of clinical research in the office setting. Hastings Center Report 32(4):22-26. Kodish, E., T. Murray, and P. Whitehouse. 1996. Conflict of interest in university-industry research relationships: realities, politics, and values. Academic Medicine 71(12): 1287-1290. Kopelow, M. 2008. Untitled. Presentation to the Institute of Medicine Committee on Conflicts of Interest in Medical Research, Education, and Practice, Washington, DC, January 21. Kovaleski, D. 2008. No Pharma Funding. http://meetingsnet.com/cmepharma/cme/ no_pharma_funding_012808/index.html (accessed January 29, 2009). Krimsky, S. 2003. Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? Lanham, MD: Rowman & Littlefield Publishers. Krimsky, S., and L. S. Rothenberg. 2001. Conflict of interest policies in science and medi- cal journals: editorial practices and author disclosures. Science and Engineering Ethics 7(2):205-218. Krimsky, S., L. S. Rothenberg, P. Stott, and G. Kyle. 1996. Financial interests of authors in scientific journals: a pilot study of 14 publications. Science and Engineering Ethics 2(4):395-410. Kuehn, B. M. 2005. Pharmaceutical industry funding for residencies sparks controversy. Jour- nal of the American Medical Association 293(13):1572-1580. Kulynych, J. J. 2007. Some thoughts about the evaluation of non-clinical functional magnetic resonance imaging. American Journal of Bioethics 7(9):57-58. Kurth, T., J. M. Gaziano, N. R. Cook, G. Logroscino, H. C. Diener, and J. E. Buring. 2006. Migraine and risk of cardiovascular disease in women. Journal of the American Medical Association 296(3):283-291. Lagnado, M. 2002. Haunted papers. Lancet 359(9309):902. Lahiri, S., C. Levenstein, D. I. Nelson, and B. J. Rosenberg. 2005. The cost effectiveness of occupational health interventions: prevention of silicosis. American Journal of Industrial Medicine 48(6):503-514. Landefeld, C. S., and M. A. Steinman. 2009. The Neurontin legacyâmarketing through mis- information and manipulation. New England Journal of Medicine 360(2):103-106. Landrum, M. B., B. J. McNeil, L. Silva, and S. L. Normand. 1999. Understanding variability in physician ratings of the appropriateness of coronary angiography after acute myocardial infarction. Journal of Clinical Epidemiology 52(4):309-319. Lane, K., and R. Berkow. 1999. The Merck Manual: a century of medical publishing and practice. CBE Views 22(4):112-113. Langwell, K. M., and L. M. Nelson. 1986. Physician payment systems: a review of history, alternatives and evidence. Medical Care Review 43(1):5-58. Larson, R. J., L. M. Schwartz, S. Woloshin, and H. G. Welch. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2005. Advertising by academic medical centers. Archives of Internal Medicine 165(6):645-651. Lauer, M. S. 2007. Screening for coronary heart disease: has the time for universal imaging arrived? Cleveland Clinic Journal of Medicine 74(9):645-650, 653-654, 656.
REFERENCES 265 Lazar, K. 2008. Legislature votes to crack down on companiesâ gifts to doctors. Boston Globe Online, July 31. http://www.boston.com/news/local/breaking_news/2008/07/legislature_ vot.html (accessed August 12, 2008). LCME (Liaison Committee on Medical Education). 2008. Accreditation Standards. http:// www.lcme.org/standard.htm (accessed August 12, 2008). Lee, K., P. Bacchetti, and I. Sim. 2008. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Medicine 5(9):e191. Lemmens, T. 2004. Piercing the veil of corporate secrecy about clinical trials. Hastings Center Report 34(5):14-18. Lemmens, T., and P. B. Miller. 2003. The human subjects trade: ethical and legal issues sur- ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ rounding recruitment incentives. Journal of Law, Medicine and Ethics 31(3):398-418. Lemmens, T., and P. A. Singer. 1998. Bioethics for clinicians. 17. Conflict of interest in research, ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ education and patient care. Canadian Medical Association Journal 159(8):960-965. Lenzer, J. 2002. Alteplase for stroke: money and optimistic claims buttress the âbrain attackâ campaign. British Medical Journal 324(7339):723-729. Lenzer, J. 2008. Truly independent research? British Medical Journal 337:a1332. Lesser, L. I., C. B. Ebbeling, M. Goozner, D. Wypij, and D. S. Ludwig. 2007. Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Medicine 4(1):e5. Lever, A., and S. Z. Lewis. 2008. Conflicts of interest in evidence-based guidelines: issues and solutions. Presentation for the American College of Chest Physicians to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Prac- tice, Washington, DC, May 22. Levine, M. 2008. Untitled. Presentation for the American Medical Association to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, March 13. Levinsky, N. G. 2002. Nonfinancial conflicts of interest in research. New England Journal of Medicine 347(10):759-761. Levinson, W., A. Kao, A. M. Kuby, and R. A. Thisted. 2005. The effect of physician disclosure of financial incentives on trust. Archives of Internal Medicine 165(6):625-630. Lexchin, J., L. A. Bero, B. Djulbegovic, and O. Clark. 2003. Pharmaceutical industry spon- sorship and research outcome and quality: systematic review. British Medical Journal 326(7400):1167-1170. Lilly (Eli Lilly and Company). 2008. Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments. Indianapolis, IN: Lilly. http://newsroom.lilly. com/releasedetail.cfm?ReleaseID=336444 (accessed November 5, 2008). Lipton, S., E. A. Boyd, and L. A. Bero. 2004. Conflicts of interest in academic research: poli- cies, processes, and attitudes. Accountability in Research 11(2):83-102. Lo, B. 2001. Ethical and policy implications of hospitalist systems. American Journal of Medicine 111(9B):48-52. Lo, B., L. E. Wolf, and A. Berkeley. 2000. Conflict-of-interest policies for investigators in clini- cal trials. New England Journal of Medicine 343(22):1616-1620. Loftus, P. 2008. Pfizer ends direct funding of courses. Wall Street Journal, July 3, B11. Lohr, K. N. 2004. Rating the strength of scientific evidence: relevance for quality improvement programs. International Journal for Quality in Health Care 16(1):9-18. Lopes, M. J. 2009. Request for Final Promulgation of 105 C.M.R. 970.000. Memorandum to the members of the Public Health Council, Boston, MA. http://www.mass.gov/Eeohhs2/ docs/dph/legal/pharmacy_med_device_phc_memo_march12.doc (accessed March 13, 2009).
266 CONFLICT OF INTEREST Lu, C. Y., D. Ross-Degnan, S. B. Soumerai, and S. A. Pearson. 2008. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literatureâ2001-2007. BMC Health Services Research 8:75. Lurie, P. 2007. Untitled. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, November 5. Lurie, P., C. M. Almeida, N. Stine, A. R. Stine, and S. M. Wolfe. 2006. Financial conflict of inter- est disclosure and voting patterns at Food and Drug Administration Drug Advisory Com- mittee meetings. Journal of the American Medical Association 295(16):1921-1928. Lurker, N., and B. Caprara. 2005. The sampling subsidy: Pharma canât afford to kill it or continue it. Alternatives are needed now. Pharmaceutical Executive, February 2005. http://www.impactrx.com/pdfs/PharmaExec_Feb05_Sampling.pdf (accessed August 27, 2007). Maatz, C. T. 1992. University physician-researcher conflicts of interest: the inadequacy of cur- rent controls and proposed reform. High Technology Law Journal 7:137-188. Mainous, A. G., III, W. J. Hueston, and E. C. Rich. 1995. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. Archives of Family Medicine 4(4):335-339. Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, et al. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal anti- body therapy in patients with relapsed low-grade non-Hodgkinâs lymphoma. Blood 90(6):2188-2195. Manchanda, P., and P. K. Chintagunta. 2004. Responsiveness of physician prescription behav- ior to salesforce effort: an individual level analysis. Marketing Letters 15(2-3):129-145. Manchanda, P., and E. Honka. 2005. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale Journal of Health, Policy, Law, and Ethics 5(2):785-822. Marco, C. A., and T. A. Schmidt. 2004. Who wrote this paper? Basics of authorship and ethi- cal issues. Academic Emergency Medicine 11(1):76-77. Marco, C. A., J. C. Moskop, R. C. Solomon, J. M. Geiderman, and G. L. Larkin. 2006. Gifts to physicians from the pharmaceutical industry: an ethical analysis. Annals of Emergency Medicine 48(5):513-521. Martinson, B. C., M. S. Anderson, and R. de Vries. 2005. Scientists behaving badly. Nature ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 435(7043):737-738. MarusiÄ, A., T. Bates, A. Anic, and M. MarusiÄ. 2006. How the structure of contribution dis- closure statements affects validity of authorship: a randomized study in a general medical journal. Current Medical Research and Opinion 22(6):1035-1044. Maskell, J. 2007. Entering the Executive Branch of Government: Potential Conflicts of Inter- est with Previous Employments and Affiliations. CRS Report for Congress, Order Code RL31822. Washington, DC: Congressional Research Service. http://www.fas.org/sgp/crs/ misc/RL31822.pdf (accessed August 1, 2008). Masur, H. 2007. From the President: IDSA Practice Guidelines: Valuable, Credible, Flexible. IDSA News, January 1. http://www.idsociety.org/newsArticle.aspx?id=5472 (accessed August 19, 2008). Mathews, A. W. 2005. Ghost story: at medical journals, writers paid by industry play big role. Wall Street Journal, December 13, A1, A8. Matteson, E. L., and T. Bongartz. 2006. Investigation, explanation, and apology for incomplete and erroneous disclosures. Journal of the American Medical Association 296(18):2205. Matz, R. 1996. Inflating physiciansâ expectations. Journal of General Internal Medicine 11(1):62-63.
REFERENCES 267 Mazmanian, P. E. 2007. Theory and evidence to explain guidelines, variation, and risk of unwanted influence. Journal of Continuing Education in the Health Professions 27(4):199-200. Mazzaschi, A. 1990. NIH and ADAMHAâs conflict-of-interest guidelines withdrawn. FASEB Journal 4(2):137-138. McCanse, C. 2001. AMA initiative aims to heighten awareness of gift-giving guidelines. FP Report 7(9), Leawood, KS: American Academy of Family Physicians. http://www.aafp. org/fpr/20010900/07.html (accessed July 28, 2008). McClure, S. M., M. K. York, and P. R. Montague. 2004. The neural substrates of reward processing in humans: the modern role of FMRI. Neuroscientist 10(3):260-268. McCormick, B. B., G. Tomlinson, P. Brill-Edwards, and A. S. Detsky. 2001. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. Journal of the American Medical Association 286(16):1994-1999. McCrary, S. V., C. B. Anderson, J. Jakovljevic, T. Khan, L. B. McCullough, N. P. Wray, and B. A. Brody. 2000. A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal of Medicine 343(22):1621-1626. McCrory, D. C., S. Z. Lewis, J. Heitzer, G. Colice, and W. M. Alberts. 2007. Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl.):23S-28S. McDonagh, A. F. 2001. Phototherapy: from ancient Egypt to the new millennium. Journal of Perinatology 21(Suppl. 1):S7-S12. McFadden, D. W., E. Calvario, and C. Graves. 2007. The devil is in the details: the pharma- ceutical industryâs use of gifts to physicians as marketing strategy. Journal of Surgical Research 140(1):1-5. McKinney, W. P., D. L. Schiedermayer, N. Lurie, D. E. Simpson, J. L. Goodman, and E. C. Rich. 1990. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. Journal of the American Medical Association 264(13):1693-1697. McLaughlin, J. K., J. D. Boice, Jr., R. E. Tarone, and W. J. Blot. 2007. A rebuttal: secret ties to industry and conflicting interests in cancer research. American Journal of Industrial Medicine 50(3):235-236. McMahon, B. J., R. Neubauer, B. Janis, S. Tucker, and M. Agnew. 2003. Developing and ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ implementing a program of grand rounds for internists that is free of commercial bias. Annals of Internal Medicine 139(1):77-78. McNeil, B., and M. Roberts. 1991. The evolution and current status of conflict of interest regulation in biomedical science. In Patient Outcomes Research Teams (PORTS): Manag- ing Conflict of Interest. Washington, DC: National Academy Press. Medical News Today. 2007. APA Names DSM-V Task Force Members-Leading Experts to Revise Handbook for Diagnosing Mental Disorders, USA. http://www.medicalnewstoday. com/articles/77663.php (accessed September 25, 2008). MedPAC (Medicare Payment Advisory Commission). 2005a. Report to the Congress: Medi- care Payment Policy. Washington, DC: MedPAC. http://www.medpac.gov/publications/ congressional_reports/Mar05_EntireReport.pdf (accessed September 17, 2008). MedPAC. 2005b. Report to the Congress: Physician-Owned Specialty Hospitals. Washington, DC: MedPAC. http://www.medpac.gov/documents/Mar05_SpecHospitals.pdf (accessed September 17, 2008). MedPAC. 2005c. Strategies to improve care: pay for performance and information technol- ogy. In Report to the Congress: Medicare Payment Policy. Washington, DC: MedPAC. http://www.medpac.gov/publications/congressional_reports/Mar05_Ch04.pdf (accessed December 15, 2008).
268 CONFLICT OF INTEREST MedPAC. 2006. Report to the Congress: Medicare Payment Policy. Washington, DC: MedPAC. http://www.medpac.gov/documents/jun06_entirereport.pdf (accessed Novem- ber 18, 2008). MedPAC. 2007. Report to the Congress: Promoting Greater Efficiency in Medicare. Wash- ington, DC: MedPAC. http://www.medpac.gov/documents/jun07_EntireReport.pdf (ac- cessed November 18, 2008). MedPAC. 2008a. Public reporting of physiciansâ financial relationships. MedPAC public meeting, April 9. Washington, DC: MedPAC. http://www.medpac.gov/transcripts/0408_ Public_reporting_phys_relationships_public_pres.pdf (accessed January 13, 2009). MedPAC. 2008b. Public Reporting of Physiciansâ Financial Relationships: Draft Recommen- dations. MedPAC public meeting, October 2. Washington, DC: MedPAC. http://www. medpac.gov/transcripts/Public%20reporting_Oct%2008_public.pdf (accessed January 13, 2009). MedPAC. 2008c. Public Reporting of Physiciansâ Financial Relationships: Policy Options. MedPAC public meeting, September 4. Washington, DC: MedPAC. http://www.medpac. gov/transcripts/Public%20reporting%20physician%20relationships_Sept%2008_public. pdf (accessed January 13, 2009). MedPAC. 2008d. Public Reporting of Physiciansâ Financial Relationships with Drug and Device Manufacturers, Hospitals, and ASCs. MedPAC public meeting, March 5. Washington, DC: MedPAC. http://www.medpac.gov/transcripts/Public%20reporting_ physicians%20relationships_final.pdf (accessed January 13, 2009). MedPAC. 2009. Report to the Congress: Medicare Payment Policy. Washington, DC: MedPAC. http://www.medpac.gov/documents/Mar09_EntireReport.pdf (accessed March 8, 2009). Melander, H., J. Ahlqvist-Rastad, G. Meijer, and B. Beermann. 2003. Evidence b(i)ased medicineâselective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal 326(7400):1171-1173. Mello, M. M., B. R. Clarridge, and D. M. Studdert. 2005a. Academic medical centersâ stan- dards for clinical-trial agreements with industry. New England Journal of Medicine 352(21):2202-2210. Mello, M. M., B. R. Clarridge, and D. M. Studdert. 2005b. Researchersâ views of the ac- ceptability of restrictive provisions in clinical trial agreements with industry sponsors. Accountability in Research 12(3):163-191. Merton, R. K. 1968. Social Theory and Social Structure. New York: The Free Press. MGMA (Medical Group Management Association). 2008. Specialty Physician Compensation Barely Keeps up with Inflation. Inglewood, CO: MGMA. http://www.mgma.com/press/ article.aspx?id=20662 (accessed September 17, 2008). Mike, V., A. N. Krauss, and G. S. Ross. 1996. Doctors and the health industry: a case study of transcutaneous oxygen monitoring in neonatal intensive care. Social Science and Medicine 42(9):1247-1258. Millenson, M. 2003. Getting Doctors to Say Yes to Drugs: The Cost and Quality of Impact of Drug Company Marketing to Physicians. http://www.bcbs.com/betterknowledge/cost/ Drug_Co_Marketing_Report.pdf (accessed June 27, 2007). Miller, D. P., R. J. Mansfield, J. B. Woods, J. L. Wofford, and W. P. Moran. 2008. The impact of drug samples on prescribing to the uninsured. Southern Medical Journal 101(9):888-893. Miller, G. 2005. Neuroscience. Economic game shows how the brain builds trust. Science 308(5718):36. Mirowski, P., and R. Van Horn. 2005. The contract research organization and the commer- cialization of scientific research. Social Studies of Science 35(4):503-548.
REFERENCES 269 MIT (Massachusetts Institute of Technology). Undated. What is Coeus? http://web.mit.edu/ coeus/www/coeus_description.htm (accessed November 11, 2008). Mitchell, J. M. 2008. Do financial incentives linked to ownership of specialty hospitals affect physiciansâ practice patterns? Medical Care 46(7):732-737. Mitchell, J. M., and E. Scott. 1992. Physician self-referral: empirical evidence and policy im- plications. Advances in Health Economics and Health Services Research 13:27-42. Moher, D., D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D. F. Stroup. 1999. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-Analyses. Lancet 354(9193):1896-1900. Moher, D., K. F. Schulz, and D. G. Altman. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2001. The CONSORT statement: revised recom- mendations for improving the quality of reports of parallel-group randomised trials. Annals of Internal Medicine 134(8):657-662. Monmaney, T. 2000. Top medical journal admits 19 lapses of ethics policy. The Los Angeles Times, February 24, A1. Montague, B. T., A. H. Fortin VI, and J. Rosenbaum. 2008. A systematic review of curricula on relationships between residents and the pharmaceutical industry. Medical Education 42(3):301-308. Moore, D. A., D. M. Cain, G. Loewenstein, and M. H. Bazerman. 2005. Conflicts of Inter- est: Challenges and Solutions in Business, Law, Medicine, and Public Policy. New York: Cambridge University Press. Morgan, M. A., J. Dana, G. Loewenstein, S. Zinberg, and J. Schulkin. 2006. Interactions of doctors with the pharmaceutical industry. Journal of Medical Ethics 32(10):559-563. Moses, H. 2008. Conflict of interest in basic and translational biomedical research. Presenta- tion to the Institute of Medicine Committee on Conflicts of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. Moses, H., and J. B. Martin. 2001. Academic relationships with industry: a new model for biomedical research. Journal of the American Medical Association 285(7):933-935. Moses, H., E. R. Dorsey, D. H. Matheson, and S. O. Thier. 2005. Financial anatomy of bio- medical research. Journal of the American Medical Association 294(11):1333-1342. Mowatt, G., L. Shirran, J. M. Grimshaw, D. Rennie, A. Flanagin, V. Yank, G. MacLennan, P. C. Gotzsche, and L. A. Bero. 2002. Prevalence of honorary and ghost authorship in Cochrane reviews. Journal of the American Medical Association 287(21):2769-2771. Mowery, D. C., R. R. Nelson, B. N. Sampat, and A. A. Ziedonis. 2001. The growth of patent- ing and licensing by U.S. universities: an assessment of the effects of the Bayh-Dole Act of 1980. Research Policy 30:99-119. Mowery, D. C., R. R. Nelson, B. N. Sampat, and A. A. Ziedonis. 2004. Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act in the United States. Stanford, CA: Stanford Business Books. Murphy, M. K., N. A. Black, D. L. Lamping, C. M. McKee, C. F. Sanderson, J. Askham, and T. Marteau. 1998. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment 2(3):i-iv, 1-88. NAAMECC (North American Association of Medical Education and Communication Com- panies). 2009. Welcome to NAAMECC. Birmingham, AL: NAAMECC. http://naamecc. org/ (accessed March 22 2009). NAAMECC and Coalition for Healthcare Communication. 2008. Critical Concerns with Ac- curacy and Validity of âReport 1 of the Council on Ethical and Judicial Affairs: Industry Support of Professional Education in Medicine.â Letter to M. Levine (AMA) and R. Christensen (AMA), May 22. http://www.acme-assn.org/home/NAAMECC_CEJA.pdf (accessed September 25, 2008).
270 CONFLICT OF INTEREST Naghavi, M., E. Falk, H. S. Hecht, M. J. Jamieson, S. Kaul, D. Berman, Z. Fayad, et al. 2006. From vulnerable plaque to vulnerable patient. Part III: Executive summary of the Screen- ing for Heart Attack Prevention and Education (SHAPE) Task Force report. American Journal of Cardiology 98(2A):2H-15H. Nallamothu, B. K., J. Young, H. S. Gurm, G. Pickens, and K. Safavi. 2007. Recent trends in hospital utilization for acute myocardial infarction and coronary revascularization in the United States. American Journal of Cardiology 99(6):749-753. NASS (North American Spine Society). 2007. Diagnosis and Treatment of Degenerative Lum- bar Spinal Stenosis. Burr Ridge, IL: NASS. p. 133. NASS. 2008. Diagnosis and Treatment of Degenerative Lumbar Spondylolisthesis. Burr Ridge, IL: NASS. p. 131. NBAC (National Bioethics Advisory Commission). 2001. Ethical and Policy Issues in Research Involving Human Participants. Bethesda, MD: NBAC. http://bioethics.georgetown.edu/ nbac/human/oversumm.pdf (accessed December 12, 2008). NEJM (New England Journal of Medicine). 2008. Financial Disclosure & Authorship Form. http://authors.nejm.org/help/disclosRev.pdf (accessed September 15, 2008). Ngai, S., J. L. Gold, S. S. Gill, and P. A. Rochon. 2005. Haunted manuscripts: ghost authorship in the medical literature. Accountability in Research 12(2):103-114. NGC (National Guideline Clearinghouse). 2009a. ACR Practice Guideline for the Performance of Total Body Irradiation. Rockville, MD: NGC. http://www.guideline.gov/summary/sum- mary.aspx?doc_id=10914&nbr=5694&ss=6&xl=999#s25 (accessed March 9, 2009). NGC. 2009b. Assessment: Use of Epidural Steroid Injections to Treat Radicular Lumbosacral Pain. Report of the Therapeutics and Technology Assessment Subcommittee of the Amer- ican Academy of Neurology. Rockville, MD: NGC. http://www.guideline.gov/summary/ summary.aspx?doc_id=10717&nbr=5580#s25 (accessed January 13, 2009). NGC. 2009c. Bronchial Intraepithelial Neoplasia/Early Central Airways Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines. Rockville, MD: NGC. http://www.guideline. gov/summary/summary.aspx?doc_id=11414&nbr=5933 (accessed January 13, 2009). NGC. 2009d. Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Up- date by the Infectious Diseases Society of America. Rockville, MD: NGC. http://www. guideline.gov/summary/summary.aspx?view_id=1&doc_id=12589#s25&nbr=6497&ss= 6&xl=999 (accessed April 06, 2009). NGC. 2009e. Diagnosis and Treatment of Degenerative Lumbar Spondylolisthesis. Rock- ville, MD: NGC. http://www.guideline.gov/summary/summary.aspx?view_id=1&doc_ id=12680#s25 (accessed January 13, 2009). NGC. 2009f. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Rockville, MD: NGC. http://www.guideline.gov/summary/summary. aspx?doc_id=9738&nbr=5212#s25 (accessed January 13, 2009). NGC. 2009g. Recommended Adult Immunization Schedule: United States, October 2007- September 2008. Rockville, MD: NGC. http://www.guideline.gov/summary/summary. aspx?doc_id=11679&nbr=006028&string (accessed March 10, 2009). NGC. 2009h. Updated Clinical Practice Guidelines for the Prevention and Treatment of Mu- cositis. Rockville, MD: NGC. http://www.guidelines.gov/summary/summary.aspx?doc_i d=12094&nbr=006223&string=irradiation (accessed January 13, 2009). NHRPAC (National Human Research Protections Advisory Committee). 2001. NHRPAC Recommendations on HHSâs Draft Interim Guidance on Financial Relationships in Clinical Research. Washington, DC: NHRPAC. http://www.hhs.gov/ohrp/nhrpac/mtg12- 00/finguid.htm (accessed March 10, 2009). Nicholson, S., M. V. Pauly, A. Y. Wu, J. F. Murray, S. M. Teutsch, and M. L. Berger. 2008. Get- ting real performance out of pay-for-performance. Milbank Quarterly 86(3):435-457.
REFERENCES 271 NIH (National Institutes of Health). 1995. Objectivity in research. In NIH Guide 24(25). Bethesda, MD: NIH. http://grants2.nih.gov/grants/guide/notice-files/not95-179.html (ac- cessed February 11, 2009). NIH. 2002. Financial Conflict of Interest: Objectivity in Research. Bethesda, MD: NIH. http:// grants1.nih.gov/grants/policy/coi/nih_review.htm (accessed November 12, 2008). NIH. 2004. Report of the National Institutes of Health Blue Ribbon Panel on Conflict of In- terest Policies. Bethesda, MD: NIH. http://www.nih.gov/about/ethics_COI_panelreport. pdf (accessed December 29, 2008). NIH. 2005. Summary of NIH-Specific Amendments to Conflict of Interest Ethics Regulations. Bethesda, MD: NIH. http://www.nih.gov/about/ethics/summary_amendments_08252005. htm (accessed November 12, 2008). NIH. 2007. Targeted Site Reviews on Financial Conflict of Interest: Observations. Bethesda, MD: NIH. http://grants.nih.gov/grants/policy/coi/TSR_Observations_2-14-2007.doc (ac- cessed July 17, 2008). NIH. 2008a. Frequently Asked Questions: Responsibility of Applicants for Promoting Objec- tivity in Research for Which PHS Funding Is Sought. Bethesda, MD: NIH. http://grants. nih.gov/grants/policy/coifaq.htm#a2 (accessed June 23, 2008). NIH. 2008b. NIH Announces a New Business Process for Reporting an Identified Financial Conflict of Interest for Grants and/or Cooperative Agreements Beginning October 10, 2008. NIH announcement Notice NOT-OD-09-001. Bethesda, MD: NIH. http://grants. nih.gov/grants/guide/notice-files/NOT-OD-09-001.html (accessed February 19, 2009). NIH. 2008c. Re-Engineering the Clinical Research Enterprise: Clinical Research Policy Analy- sis and Coordination. Bethesda, MD: NIH. http://nihroadmap.nih.gov/clinicalresearch/ overview-policy.asp (accessed July 3, 2008). NIH. 2008d. Re-Engineering the Clinical Research Enterprise: Translational Research. Bethesda, MD: NIH. http://nihroadmap.nih.gov/clinicalresearch/overview-translational. asp (accessed July 3, 2008). NIH. Undated. NIH Consensus Development Program: About Us. Bethesda, MD: NIH. http:// consensus.nih.gov/ABOUTCDP.htm#panel (accessed June 23, 2008). Nissen, S. E. 2006. Presidentâs page: American College of Cardiology fellowship: where ide- als and personal responsibility intersect. Journal of the American College of Cardiology 47(9):1901-1903. Nix, M. 2008. Guideline methodology: National Guideline Clearinghouseâ¢ (NGC) data. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. NKF (National Kidney Foundation). 2007. KDOQI Disclosure and COI Policies. New York, NY: NKF. http://www.kidney.org/professionals/KDOQI/guidelinesCOI.cfm (accessed February 23, 2009). NLM (National Library of Medicine). 2007. Fact Sheet: Conflict of Interest Disclosure and Journal Supplements in MEDLINEÂ®. Bethesda, MD: NLM. http://www.nlm.nih.gov/ pubs/factsheets/supplements.html (accessed February 27, 2009). Northfield Laboratories. 2006. Northfield Laboratories Releases Summary Observations from Its Elective Surgery Trial. http://phx.corporate-ir.net/phoenix.zhtml?c=91374&p=irol- newsArticle&ID=833808&highlight= (accessed October 10, 2008). NPG (Nature Publishing Group). 2007. Compete, collaborate, compel. Nature Genetics 39(8):931. (Editorial.) NPG. 2008. Competing Financial Interests. http://www.nature.com/authors/editorial_policies/ competing.html (accessed September 15, 2008). NRC (National Research Council). 2003. Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences. Washington, DC: The National Academies Press.
272 CONFLICT OF INTEREST Nuckols, T. K., Y. W. Lim, B. O. Wynn, S. Mattke, C. H. MacLean, P. Harber, R. H. Brook, et al. 2008. Rigorous development does not ensure that guidelines are acceptable to a panel of knowledgeable providers. Journal of General Internal Medicine 23(1):37-44. OâBrien, M. A., A. D. Oxman, D. A. Davis, R. B. Haynes, N. Freemantle, and E. L. Harvey. 2000. Educational outreach visits: effects on professional practice and health care out- comes. Cochrane Database of Systematic Reviews (2):CD000409. OIG (Office of the Inspector General, U.S. Department of Health and Human Services). 1989. Financial Arrangements Between Physicians and Health Care Businesses. Washington, DC: U.S. Department of Health and Human Services. http://www.oig.hhs.gov/oei/reports/ oai-12-88-01411.pdf (accessed November 18, 2008). OIG. 2003. Compliance Program Guidance for Pharmaceutical Manufacturers. Washington, DC: U.S. Department of Health and Human Services. http://www.oig.hhs.gov/fraud/docs/ complianceguidance/042803pharmacymfgnonfr.pdf (accessed February 13, 2009). OIG. 2004. Corporate Integrity Agreement Between the Office of Inspector General of the Department of Health and Human Services and Pfizer, Inc. Washington, DC: U.S. De- partment of Health and Human Services. http://www.oig.hhs.gov/fraud/cia/agreements/ pfizer_5_11_2004.pdf (accessed December 12, 2008). OIG. 2005. Outside Activities of Senior-Level NIH Employees. Washington, DC: U.S. Depart- ment of Health and Human Services. http://oig.hhs.gov/oei/reports/oei-01-04-00150.pdf (accessed November 11, 2008). OIG. 2007. Corporate Integrity Agreement Between the Office of Inspector General of De- partment of Health and Human Services and Jazz Pharmaceuticals, Inc. Washington, DC: U.S. Department of Health and Human Services. http://oig.hhs.gov/fraud/cia/agreements/ Jazz%20CIA.pdf (accessed June 10, 2009). OIG. 2008. National Institutes of Health: Conflicts of Interest in Extramural Research. Washington, DC: U.S. Department of Health and Human Services. http://oig.hhs.gov/ oei/reports/oei-03-06-00460.pdf (accessed June 23, 2008). OIG. 2009. The Food and Drug Administrationâs Oversight of Clinical Investigatorâs Financial Information. Washington, DC: U.S. Department of Health and Human Services. http:// oig.hhs.gov/oei/reports/oei-05-07-00730.pdf (accessed February 27, 2009). OIG. Undated. Corporate Integrity Agreements. Washington, DC: U.S. Department of Health and Human Services. http://www.oig.hhs.gov/fraud/cias.asp (accessed October 29, 2008). Oncology Congress. 2008. Educational Grants. http://www.oncologycongress.com/app/ homepage.cfm?appname=100432&moduleID=2147&LinkID=18209 (accessed Novem- ber 21, 2008). Oncology Congress. 2009. Industry-Supported Satellite Symposia Opportunities. http:// www.oncologycongress.com/app/homepage.cfm?appname=100432&moduleID=2147& LinkID=18089 (accessed January 27, 2009). Oregon DOJ (Department of Justice). 2008a. AG Hardy Myers Files Judgment Against Merck; Oregon is Lead State in $58 million settlement. Press release, July 13. Salem: Oregon DOJ. http://www.doj.state.or.us/releases, 2008/rel052008.shtml (accessed September 25, 2008). Oregon DOJ. 2008b. AG Myers Files Judgment Against Pfizer for $60 Million Concerning Itâs Marketing of Drugs Celebrex & Bextra. Press release, October 22. Salem: Oregon DOJ. http://www.doj.state.or.us/releases/2008/rel102208.shtml (accessed November 13, 2008). OâReilly, K. B. 2006. AMA opt-out program will keep prescribing data from drug reps. American Medical News, May 22/29. http://www.ama-assn.org/amednews/2006/05/22/ prl10522.htm (accessed March 2, 2009).
REFERENCES 273 OâReilly, K. B. 2008. Drugmakers vow to disclose their payments to physicians. American Medical News, November 17. http://www.ama-assn.org/amednews/2008/11/17/prsa1117. htm (accessed December 2, 2008). ORI (Office of Research Integrity). 2008. About ORI: History. Rockville, MD: ORI. http://ori. dhhs.gov/about/history.shtml (accessed February 10, 2009). Orlowski, J. P., and L. Wateska. 1992. The effects of pharmaceutical firm enticements on physi- cian prescribing patterns. Thereâs no such thing as a free lunch. Chest 102(1):270-273. OTA (Office of Technology Assessment). 1984. Commercial Biotechnology: An International Analysis. Report OTA-BA-218. Washington, DC: U.S. Government Printing Office. OTA. 1986. Payment for Physician Services: Strategies for Medicare. Report OTA-H-294. Washington, DC: U.S. Government Printing Office. OTA. 1994. Identifying Health Technologies That Work: Searching for Evidence. Report OTA-H-608. Washington, DC: U.S. Government Printing Office. Oxman, A. D. 1994. Checklists for review articles. British Medical Journal 309(6955): 648-651. Oxman, A. D., H. J. Schunemann, and A. Fretheim. 2006a. Improving the use of research ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ evidence in guideline development. 2. Priority setting. Health Research Policy and Sys- tems 4:14. Oxman, A. D., H. J. Schunemann, and A. Fretheim. 2006b. Improving the use of research ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ evidence in guideline development. 8. Synthesis and presentation of evidence. Health Research Policy and Systems 4:20. Papanikolaou, G. N., M. S. Baltogianni, D. G. Contopoulos-Ioannidis, A. B. Haidich, I. A. Giannakakis, and J. P. Ioannidis. 2001. Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions. BMC Medical Research Methodology 1:3. Parascandola, M. 2007. A turning point for conflicts of interest: the controversy over the Na- tional Academy of Sciencesâ first conflicts of interest disclosure policy. Journal of Clinical Oncology 25(24):3774-3779. Pear, R. 2008. Long-term fix is elusive in Medicare payments. The New York Times, July 13, A18. Pearson, S. D., K. Kleinman, D. Rusinak, and W. Levinson. 2006. A trial of disclosing physi- ciansâ financial incentives to patients. Archives of Internal Medicine 166(6):623-628. Pellegrino, E. D., and A. S. Relman. 1999. Professional medical associations: ethical and prac- tical guidelines. Journal of the American Medical Association 282(10):984-986. Pellegrino, E. D., and D. C. Thomasma. 1993. Virtues in Medical Practice. New York: Oxford University Press. Peppercorn, J., E. Blood, E. Winer, and A. Partridge. 2007. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109(7):1239-1246. Perkins, H. S. 1995. May the piper take payment and still call the tune? Journal of General Internal Medicine 10(11):645-646. Perlis, R. H., C. S. Perlis, Y. Wu, C. Hwang, M. Joseph, and A. A. Nierenberg. 2005. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychia- try. American Journal of Psychiatry 162(10):1957-1960. Perrone, M. 2009. Drugmakersâ push boosts âmurkyâ ailment. The Associated Press, Febru- ary 8. http://abcnews.go.com/Business/WireStory?id=6831203&page=3 (accessed April 8, 2009). Perry, S. 1982. Special report. The brief life of the National Center for Health Care Technol- ogy. New England Journal of Medicine 307(17):1095-1100. Petersen, M. 2003. Science journals tighten rules for disclosure of financial ties. The New York Times, September 27, A10.
274 CONFLICT OF INTEREST Pettypiece, S. 2007. Pfizer job cuts may prompt Glaxo, Sanofi to follow. Bloomberg Online News, January 23. http://www.bloomberg.com/apps/news?pid=20601087&sid=ag94zZ TfJ4h4&refer=home (accessed August 12, 2008). Pfizer. 2008. Pfizer Changes Its Funding of Continuing Medical Education in the U.S. New York, NY: Pfizer. https://www.pfizermededgrants.com/pfizercme/help/CME_Funding_ Change_Announcement.html (accessed November 5, 2008). Pham, H. H., and P. B. Ginsburg. 2007. Unhealthy trends: the future of physician services. Health Affairs 26(6):1586-1598. Pham, H. H., K. J. Devers, J. H. May, and R. Berenson. 2004. Financial pressures spur physi- cian entrepreneurialism. Health Affairs 23(2):70-81. PhRMA (Pharmaceutical Research and Manufacturers of America). 2008. Code on Interac- tions with Healthcare Professionals. Washington, DC: PhRMA. http://www.phrma.org/ files/PhRMA%20Marketing%20Code%202008.pdf (accessed August 1, 2008). Piwowar, H. A., and W. W. Chapman. 2008. A review of journal policies for sharing research data. Proceedings of the ELPUB 2008 Conference on Electronic Publishing, Toronto, On- tario, Canada, June 2008. http://elpub.scix.net/data/works/att/001_elpub2008.content. pdf (accessed October 10, 2008). Plint, A., D. Moher, K. Schulz, D. Altman, and A. Morrison. 2005. Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Paper presented at the Fifth International Congress on Peer Review and Biomedi- cal Publication, Chicago, IL, September 16-18. Podolsky, S. H., and J. A. Greene. 2008. A historical perspective of pharmaceutical promo- tion and physician education. Journal of the American Medical Association 300(7): 831-833. Poitras, S., J. Avouac, M. Rossignol, B. Avouac, C. Cedraschi, M. Nordin, C. Rousseaux, et al. 2007. A critical appraisal of guidelines for the management of knee osteoarthritis ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ using Appraisal of Guidelines Research and Evaluation criteria. Arthritis Research & Therapy 9(6):R126. PPRC (Physician Payment Review Commission). 1987. Medicare Physician Payment: An Agenda for Reform: Annual Report to Congress, 1987. Washington, DC: PPRC. Pritchard, M. S. 1996. Conflicts of interest: conceptual and normative issues. Academic Medi- cine 71(12):1305-1313. Psaty, B. M., and R. A. Kronmal. 2008. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. Journal of the American Medical Association 299(15):1813-1817. Psaty, B. M., and D. Rennie. 2006. Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharma- ceutical industry. Journal of the American Medical Association 295(23):2787-2790. Radek, K. A., L. A. Baer, J. Eckhardt, L. A. DiPietro, and C. E. Wade. 2008. Mechanical unloading impairs keratinocyte migration and angiogenesis during cutaneous wound healing. Journal of Applied Physiology 104(5):1295-1303. Randall, D. A. 2007. The high cost of free lunch. Obstetrics and Gynecology 110(4):932; author reply 932-933. Rapp, K. 2003. New Times, New Ethical Standards: AdvaMedâs Revised Code Updates Medtech Business Practices to Meet Modern Demands for Ethical Conduct and Social Responsibility. http://www.devicelink.com/mx/archive/03/11/rapp.html (accessed March 10, 2009). Ratanawongsa, N., A. Teherani, and K. E. Hauer. 2005. Third-year medical studentsâ experi- ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ ences with dying patients during the internal medicine clerkship: a qualitative study of the informal curriculum. Academic Medicine 80(7):641-647.
REFERENCES 275 Read, J. L., and P. M. Campbell. 1988. Health care innovation: a progress report. Health Affairs 7(3):174-185. Read, J. L., and K. B. Lee, Jr. 1994. Health care innovation: progress report and focus on biotechnology. Health Affairs 13(3):215-225. Reck, J. 2008. A Template for Establishing and Administering Prescriber Support and Edu- cation Programs: A Collaborative, Service Based Approach for Achieving Maximum Impact. Hallowell, ME: Prescription Policy Choices. http://www.policychoices.org/ documents/AcademicDetailingTemplate.pdf (accessed October 29, 2008). Relman, A. S. 1984. Dealing with conflicts of interest. New England Journal of Medicine 310(18):1182-1183. Relman, A. S. 2001. Separating continuing medical education from pharmaceutical marketing. Journal of the American Medical Association 285(15):2009-2012. Relman, A. S. 2003. Defending professional independence: ACCMEâs proposed new guide- lines for commercial support of CME. Journal of the American Medical Association 289(18):2418-2420. Relman, A. S. 2008. Industry support of medical education. Journal of the American Medical Association 300(9):1071-1073. Renfrew, M. J., L. Dyson, G. Herbert, A. McFadden, F. McCormick, J. Thomas, and H. Spiby. 2008. Developing evidence-based recommendations in public healthâincorporating the views of practitioners, service users and user representatives. Health Expect 11(1):3-15. Rennie, D. 1997. Thyroid storm. Journal of the American Medical Association 277(15): 1238-1243. Rennie, D., V. Yank, and L. Emanuel. 1997. When authorship fails. A proposal to make con- tributors accountable. Journal of the American Medical Association 278(7):579-585. Rettig, R. 1997. Health Care in Transition: Technology Assessment in the Private Sector. Santa Monica, CA: RAND. Rice, T. 1997. Physician payment policies: impacts and implications. Annual Review of Public Health 18:549-565. Rick, S., and G. Loewenstein. 2008. Intangibility in intertemporal choice. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 363(1511): 3813-3824. Ridgeway, J. 1968. The Closed Corporation: American Universities in Crisis. New York: Random House. Riechelmann, R. P., L. Wang, A. OâCarroll, and M. K. Krzyzanowska. 2007. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. Journal of Clinical Oncology 25(29):4642-4647. Rising, K., P. Bacchetti, and L. Bero. 2008. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Medicine 5(11):1561-1570. Rochon, P. A., J. H. Gurwitz, C. M. Cheung, J. A. Hayes, and T. C. Chalmers. 1994. Evaluat- ing the quality of articles published in journal supplements compared with the quality of those published in the parent journal. Journal of the American Medical Association 272(2):108-113. Rockhold, F. W., and S. Snapinn. 2007. Improving the image of pharmaceutical industry research: transparency is not always clear. Biopharmaceutical Report 15(1):2-12. http:// www.amstat.org/sections/sbiop/br_winter07.pdf (accessed February 22, 2009). Rodwin, M. 1996. Physiciansâ conflicts of interest in HMOs and hospitals. In Conflicts of Interest in Clinical Practice and Research, edited by R. G. Spece, D. S. Shimm, and A. E. Buchanan. New York: Oxford University Press. Rose, J. 2008. Industry influence in the creation of pay-for-performance quality measures. Quality Management in Health Care 17(1):27-34.
276 CONFLICT OF INTEREST Rosenthal, E. 2008. Drug makersâ push leads to vaccinesâ fast rise. The New York Times, August 20, A1. Rosenthal, M. B., B. E. Landon, K. Howitt, H. R. Song, and A. M. Epstein. 2007. Climbing up the pay-for-performance learning curve: where are the early adopters now? Health Affairs 26(6):1674-1682. Ross, J. S., P. Lurie, and S. M. Wolfe. 2000. Medical Education Services Suppliers: A Threat to Physician Education. Washington, DC: Public Citizen. http://take-back-the-power. org/publications/release.cfm?ID=7142 (accessed October 10, 2008). Ross, J. S., J. E. Lackner, P. Lurie, C. P. Gross, S. Wolfe, and H. M. Krumholz. 2007. Pharmaceu- tical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. Journal of the American Medical Association 297(11):1216-1223. Ross, J. S., K. P. Hill, D. S. Egilman, and H. M. Krumholz. 2008. Guest authorship and ghost- writing in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299(15):1800-1812. Rothman, K. J. 2001. My actual beliefs. Journal of Clinical Epidemiology 54(12):1275; author reply 1276-1277. Roughead, E. E., K. J. Harvey, and A. L. Gilbert. 1998. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Australian and New Zealand Journal of Medicine 28(3):306-310. Sackett, D., S. Straus, S. Richardson, W. Rosenberg, and R. B. Haynes. 2000. Evidence- Based Medicine: How to Practice and Teach EBM (2nd edition). London: Churchill Livingstone. SACME (Society for Academic Continuing Medical Education). 2007. Survey for 2006: Descriptive Results. SACME Biennial Survey, January. Birmingham, AL: SACME. http:// www.sacme.org/site/sacme/assets/pdf/BS_results_2006.pdf (accessed October 10, 2008). SACME. 2008a. About Us. Birmingham, AL: SACME. http://www.sacme.org/index.cfm?usec ookieval=false&pagepath=About_Us&id=1017 (accessed November 21, 2008). SACME. 2008b. SACME Response to ACCME Call for Comment on Limiting Interac- tions Between Accredited Providers and Commercial Interests over Commercial Support with Industry. Birmingham, AL: SACME. http://www.sacme.org/site/sacme/assets/pdf/ SACME_Response_to_ACCME_Calls_for_Comment_9-2008.pdf (accessed December 2, 2008). Sade, R. M. 2007. A national survey of physician-industry relationships. New England Journal of Medicine 357(5):507; author reply 508. Sadek, H., and Z. Henderson. 2004. Itâs all in the details: delivering the right informa- tion to the right rep at the right time can greatly increase sales force effectiveness. Pharmaceutical Executive, October. http://www.imshealth.com/vgn/images/portal/cit_ 40000873/2/10/71263609PE_All_in_the_Details.pdf (accessed June 27, 2007). Sage, W. M. 2007. Some principles require principals: why banning âconflicts of interestâ wonât solve incentive problems in biomedical research. Texas Law Review 85:1413-1463. Sagsveen, M. G. 2008. Untitled. Presentation for the American Academy of Neurology to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. Salsberg, E. 2008. Addressing healthcare workforce issues for the future. Statement before the Committee on Health, Education, Labor, and Pensions (HELP), U.S. Senate, February 12. http://www.aamc.org/advocacy/library/workforce/testimony/2008/021208.pdf (ac- cessed April 10, 2009). Sampat, B. N. 2006. Patenting and US academic research in the 20th century: the world before and after Bayh-Dole. Research Policy 35(6):772-789.
REFERENCES 277 San Miguel, J. F., R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, et al. 2008. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine 359(9):906-917. Sawka, A. M., and L. Thabane. 2003. Effect of industry sponsorship on the results of biomedi- cal research. Journal of the American Medical Association 289(19):2502-2503; author reply 2503. Schacht, W. H. 2008. The Bayh-Dole Act: Selected Issues in Patent Policy and the Commer- cialization of Technology. CRS Report for Congress, Order Code RL32076. Washington, DC: Congressional Research Service. http://assets.opencrs.com/rpts/RL32076_20080403. pdf (accessed December 15, 2008). Schneider, C., and A. Young. 2008. Emory puts heat on researcher. The Atlanta Journal- Constitution, October 5, A1. Schneider, J. A., V. Arora, K. Kasza, R. Van Harrison, and H. Humphrey. 2006. Residentsâ perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention. Academic Medicine 81(7):595-602. Schroter, S., J. Morris, S. Chaudhry, R. Smith, and H. Barratt. 2004. Does the type of com- peting interest statement affect readersâ perceptions of the credibility of research? Ran- domised trial. British Medical Journal 328(7442):742-743. SchÃ¼nemann, H. 2008. Systematic reviews and other strategies to protect against bias in guide- lines development. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, May 22. SchÃ¼nemann, H., A. Fretheim, and A. D. Oxman. 2006. Improving the use of research evi- dence in guideline development. 1. Guidelines for guidelines. Health Research Policy and Systems 4:13. Schwartz, L., S. Woloshin, and R. Moynihan. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ British 2008. Whoâs watching the watch dogs? Medical Journal (Clinical Research Edition) 337:a2535. Schwitzer, G., G. Mudur, D. Henry, A. Wilson, M. Goozner, M. Simbra, M. Sweet, and K. A. Baverstock. 2005. What are the roles and responsibilities of the media in disseminating health information? PLoS Medicine 2(7):e215. Seidenberg, R. 1971. Advertising and abuse of drugs. New England Journal of Medicine 284(14):789-790. Severinghaus, J. W. 2007. Takuo Aoyagi: discovery of pulse oximetry. Anesthesia and Anal- gesia 105(6 Suppl.):S1-S4, table of contents. SGIM (Society of General and Internal Medicine). 2006. Policy on Acceptance and Dis- closure of External Funds. Washington, DC: SGIM. http://www.sgim.org/userfiles/file/ SocietyInfo/ExternalFundsPolicyJan2006.pdf (accessed December 15, 2008). Shaneyfelt, T. M., M. F. Mayo-Smith, and J. Rothwangl. 1999. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. Journal of the American Medical Association 281(20):1900-1905. Shapiro, D. 2004. Drug companies get too close for med schoolâs comfort. The New York Times, January 20, F5. Shea, B. J., J. M. Grimshaw, G. A. Wells, M. Boers, N. Andersson, C. Hamel, A. C. Porter, et al. 2007. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 7:10. Shekelle, P. G., S. H. Woolf, M. Eccles, and J. Grimshaw. 1999. Clinical guidelines: developing guidelines. British Medical Journal 318(7183):593-596. Shelton, S. 2008. Emory will punish psychiatrist Nemeroff: chairmanship taken away, outside income to be vetted. The Atlanta Journal-Constitution, December 23, Metro News, 4B. http://www.ajc.com/services/content/printedition/2008/12/23/nemeroff.html (accessed February 19, 2009).
278 CONFLICT OF INTEREST Sherman, T. 2008. Cardiologist will settle fraud case: UMDNJ gave him job for referring patients. The Star-Ledger, July 1, p. 16. Shiffman, R. N., P. Shekelle, J. M. Overhage, J. Slutsky, J. Grimshaw, and A. M. Deshpande. 2003. Standardized reporting of clinical practice guidelines: a proposal from the Confer- ence on Guideline Standardization. Annals of Internal Medicine 139(6):493-498. Shuchman, M. 2007. Commercializing clinical trialsârisks and benefits of the CRO boom. New England Journal of Medicine 357(14):1365-1368. Sierles, F. S., A. C. Brodkey, L. M. Cleary, F. A. McCurdy, M. Mintz, J. Frank, D. J. Lynn, et al. 2005. Medical studentsâ exposure to and attitudes about drug company interactions: a national survey. Journal of the American Medical Association 294(9):1034-1042. Sigworth, S. K., M. D. Nettleman, and G. M. Cohen. 2001. Pharmaceutical branding of resi- dent physicians. Journal of the American Medical Association 286(9):1024-1025. Silverstein, F. E., G. Faich, J. L. Goldstein, L. S. Simon, T. Pincus, A. Whelton, R. Makuch, et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. Journal of the American Medical As- sociation 284(10):1247-1255. Simon, S. R., S. R. Majumdar, L. A. Prosser, S. Salem-Schatz, C. Warner, K. Kleinman, I. Miroshnik, et al. 2005. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. American Journal of Medicine 118(5):521-528. Sismondo, S. 2008. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials 29(2):109-113. Sloan, F. A., J. R. Rattliff, and M. A. Hall. 2007. Effects of state managed care patient protec- tion laws on physician satisfaction. Medical Care Research and Review 64(5):585-599. Smith, D. 1992. Paying for Medicare: The Politics of Reform. New York: Aldine de Gruyter. Smith, S. 2006. Article urging heart exams shows conflicting interests. Boston Globe, July 25, A1. Smulders, Y. M., and A. Thijs. 2007. The influence of the pharmaceutical industry on treatment guidelines. Nederlands Tijdschrift voor Geneeskunde 151(44):2429-2431. (In Dutch.) Snyder, L., and C. Leffler. 2005. Ethics manual: fifth edition. Annals of Internal Medicine ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 142(7):560-582. Sollitto, S., S. Hoffman, M. Mehlman, R. J. Lederman, S. J. Youngner, and M. M. Lederman. 2003. Intrinsic conflicts of interest in clinical research: a need for disclosure. Kennedy Institute of Ethics Journal 13(2):83-91. Solomon, D. H., L. Van Houten, R. J. Glynn, L. Baden, K. Curtis, H. Schrager, and J. Avorn. 2001. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Archives of Internal Medicine 161(15):1897-1902. Sorrell, W. H. 2008. Pharmaceutical Marketing Disclosures: Report of Vermont Attorney General William H. Sorrell on Payments to Physicians. Montpelier, VT: Vermont Office of the Attorney General. http://www.atg.state.vt.us/upload/1215544954_2008_Pharma- ceutical_Marketing_Disclosures_Report.pdf (accessed September 17, 2008). Soumerai, S. B., and J. Avorn. 1990. Principles of educational outreach (âacademic detail- ingâ) to improve clinical decision making. Journal of the American Medical Association 263(4):549-556. Sox, H. C., and D. Rennie. 2008. Seeding trials: just say âno.â Annals of Internal Medicine 149(4):279-280. Stanczyk, J., C. Ospelt, and S. Gay. 2008. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Current Opinion in Rheumatology 20(3):257-262. Stanford University. Undated. Stanford Research Administration: Conflict of Interest. http:// dor.stanford.edu/Resources/coi.html (accessed March 21, 2009).
REFERENCES 279 Stanford University School of Medicine. 2006. Stanford Industry Interactions Policy. http:// med.stanford.edu/coi/siip/documents/siip_policy_aug06.pdf (accessed September 15, 2008). Stanford University School of Medicine. 2008. Continuing Medical Education (CME) Com- mercial Support Policy. http://cme.stanford.edu/documents/cme_commercial_support_ policy.pdf (accessed September 15, 2008). Stark, A. 2000. Conflict of Interest in American Public Life. Cambridge, MA: Harvard Uni- versity Press. Steinberg, E. P., and B. R. Luce. 2005. Evidence based? Caveat emptor! Health Affairs ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 24(1):80-92. Steinbrook, R. 2005. Commercial support and continuing medical education. New England Journal of Medicine 352(6):534-535. Steinbrook, R. 2006. For sale: physiciansâ prescribing data. New England Journal of Medicine 354(26):2745-2747. Steinbrook, R. 2007. Guidance for guidelines. New England Journal of Medicine 356(4): 331-333. Steinbrook, R. 2008a. Disclosure of industry payments to physicians. New England Journal of Medicine 359(6):559-561. Steinbrook, R. 2008b. Financial support of continuing medical education. Journal of the American Medical Association 299(9):1060-1062. Steinbrook, R. 2008c. The Gelsinger case. In The Oxford Textbook of Clinical Research Eth- ics, edited by E. J. Emanuel, C. Grady, R. A. Crouch, R. Lie, F. Miller and D. Wendler. New York: Oxford University Press. Steinman, M. A. 2008. Conflict of interest in graduate and undergraduate medical education. Presentation to the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC, January 21. Steinman, M. A., M. G. Shlipak, and S. J. McPhee. 2001. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. American Journal of Medicine 110(7):551-557. Steinman, M. A., L. A. Bero, M. M. Chren, and C. S. Landefeld. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2006. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Annals of Internal Medicine 145(4):284-293. Steinman, M. A., G. M. Harper, M. M. Chren, C. S. Landefeld, and L. A. Bero. 2007. Char- ï¿½ï¿½ï¿½ï¿½ï¿½ acteristics and impact of drug detailing for gabapentin. PLoS Medicine 4(4):e134. Steneck, N. H. 1984. Commentary: the university and research ethics. Science, Technology, & Human Values 9(4):6-15. Stievater, D. N., A. Petersen, and R. Bhatia. 2006. Sewing up new sales. Pharmaceutical Executive, September. http://www.impactrx.com/pdfs/Sewing_Up_Sales_PharmaExec10_ 26_06.pdf (accessed August 27, 2007). Stolberg, S. G. 1999. The biotech death of Jesse Gelsinger. NYT Magazine, November 28, pp. 136-140, 149-150. Stolberg, S. G. 2000. Biomedicine is receiving new scrutiny as scientists become entrepreneurs. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ The New York Times, February 20, Sec. 1, p. 26. Stossel, T. P. 2005. Regulating academic-industrial research relationshipsâsolving problems or stifling progress? New England Journal of Medicine 353(10):1060-1065. Stossel, T. P. 2007. Regulation of financial conflicts of interest in medical practice and medi- cal research: a damaging solution in search of a problem. Perspectives in Biology and Medicine 50(1):54-71. Stossel, T. P. 2008. Has the hunt for conflicts of interest gone too far? Yes. British Medical Journal 336(7642):476. Stotland, N. 2008. APA responds to Sen. Grassley. Psychiatric News 43(17):3.
280 CONFLICT OF INTEREST Streiffer, R. 2006. Academic freedom and academic-industry relationships in biotechnology. Kennedy Institute of Ethics Journal 16(2):129-149. Stroup, D. F., J. A. Berlin, S. C. Morton, I. Olkin, G. D. Williamson, D. Rennie, D. Moher, et al. 2000. Meta-analysis of observational studies in epidemiology: a proposal for report- ing. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. Journal of the American Medical Association 283(15):2008-2012. Studdert, D. M., M. M. Mello, and T. A. Brennan. 2004. Financial conflicts of interest in ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ physiciansâ relationships with the pharmaceutical industryâself-regulation in the shadow of federal prosecution. New England Journal of Medicine 351(18):1891-1900. Sulmasy, D. P., M. G. Bloche, J. M. Mitchell, and J. Hadley. 2000. Physiciansâ ethical beliefs about cost-control arrangements. Archives of Internal Medicine 160(5):649-657. Suwa, K. 2003. Pulse oximeters: personal recollections of the past and hopes for the future. Journal of Anesthesia 17(4):267-269. Swann, J. P. 1988. Academic Scientists and the Pharmaceutical Industry. Baltimore, MD: The Johns Hopkins University Press. Symm, B., M. Averitt, S. N. Forjuoh, and C. Preece. 2006. Effects of using free sample medica- tions on the prescribing practices of family physicians. Journal of the American Board of Family Medicine 19(5):443-449. Takhar, J., D. Dixon, J. Donahue, B. Marlow, C. Campbell, I. Silver, J. Eadie, et al. 2007. Developing an instrument to measure bias in CME. Journal of Continuing Education in the Health Professions 27(2):118-123. Tanaka, M., and S. Watanabe. 1994. Overwintering in the Antarctica as an analog for long term manned spaceflight. Advances in Space Research 14(8):423-430. Tcheng, J. E., D. E. Kandzari, C. L. Grines, D. A. Cox, M. B. Effron, E. Garcia, J. J. Griffin, et al. 2003. Benefits and risks of abciximab use in primary angioplasty for acute myo- cardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 108(11):1316-1323. Tenaglia, M., and P. Angelastro. 2005. No margin for error. Pharmaceutical Executive, Sep- tember. http://www.amundsengroup.com/images/nomarginforerror.pdf (accessed August 27, 2007). Tereskerz, P. M., and J. Moreno. 2005. Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research. Accountability in Research 12(2):139-155. Thayer, A. 2005. Insulin: in Top Pharmaceuticals: a look at drugs that changed the world. Chemical & Engineering News 83(25):3. Thompson, D. F. 1993. Understanding financial conflicts of interest. New England Journal of Medicine 329(8):573-576. Thrasher, K., and M. Franklin. 1999. Minnesota sets the pace: medical technology started with a pacemaker. Minnesota Technolog, November/December. http://technolog.it.umn. edu/technolog/novdec99/pacemaker.html (accessed July 15, 2008). Tovino, S. A. 2007. Functional neuroimaging and the law: trends and directions for future scholarship. American Journal of Bioethics 7(9):44-56. Trachtman, H. 2003. The death of common sense. American Journal of Bioethics 3(3): W31-W32. Tregear, M. 2007. Guideline Heterogeneity. WorkshopâPart 2, ECRI Institute, August 27 Presentation at the Fourth Annual Guidelines International Network Meeting, Toronto on August 22-25. Tu, H. T., and P. B. Ginsburg. 2006. Losing Ground: Physician Income, 1995-2003. Tracking Report 15. Washington, DC: Center for Studying Health System Change, pp. 1-8.
REFERENCES 281 Tunis, S. R., D. B. Stryer, and C. M. Clancy. 2003. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Journal of the American Medical Association 290(12):1624-1632. Turner, E. H., A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358(3):252-260. Turton, F. E., and L. Snyder. 2007. Physician-industry relations. Annals of Internal Medicine 146(6):469. Ubel, P. A., R. M. Arnold, G. P. Gramelspacher, R. B. Hoppe, C. S. Landefeld, W. Levinson, W. Tierney, and S. W. Tolle. 1995. Acceptance of external funds by physician organizations: issues and policy options. Journal of General Internal Medicine 10(11):624-630. Ubel, P. A., C. Jepson, and D. A. Asch. 2003. Misperceptions about beta-blockers and diuret- ics: a national survey of primary care physicians. Journal of General Internal Medicine 18(12):977-983. University of California. 2008. Health Care Vendor Relations Policy. Oakland, CA: University of California. http://www.ucop.edu/ucophome/coordrev/policy/PP031208Policy.pdf (ac- cessed December 12, 2008). University of Louisville. 2008. University of Louisville Health Care Policy on Vendors. Louisville, KY: University of Louisville. http://louisville.edu/medschool/dean/docs/ VendorPolicy%20Approved.pdf (accessed December 31, 2008). University of Massachusetts. 2008. Vendor Relations Policy Frequently Asked Questions (FAQs). http://www.amsascorecard.org/documents/0000/0027/FAQs_UMM_Policy_2- 2008.doc (accessed December 31, 2008). University of Michigan. 2005. Conflicts of Interest and Conflicts of Commitment. Standard Practice Guide (Number 201.65-1). Ann Arbor: University of Michigan. http://spg.umich. edu/pdf/201.65-1.pdf (accessed July 11, 2008). University of Michigan Health System. 2007. UMHHC Policy 07-01-045: Drug Samples in UMHHC. Ann Arbor: University of Michigan Health System. http://www.imapny.org/ usr_doc/Drug_Sample_PolicyM4.pdf (accessed October 7, 2008). University of Minnesota. 2008. Potential Conflicts of Interest: A Course for University of Minnesota Researchers. St. Paul, MN: University of Minnesota. http://cflegacy.research. umn.edu/coi/index.shtml (accessed March 21, 2009). University of Pittsburgh. 2007. Industry Interactions Policy. Pittsburgh, PA: University of Pittsburgh. http://www.ogc.pitt.edu/publications/IndustryRelationshipsPolicy.pdf (ac- cessed October 7, 2008). University of Rochester. 2006. University of Rochester Policy on Institutional Conflict of Inter- est in Research Activities. Rochester, NY: University of Rochester. http://www.rochester. edu/ORPA/policies/COIresearch.pdf (accessed January 13, 2009). University of Washington. 2008. State Ethics Act of 2005âImpact on UW Policy. Seattle: Univer- sity of Washington. http://www.washington.edu/research/main.php?page=stateEthicsAct (accessed October 21, 2008). University of Wisconsin. 2008. Showcase: Campus-Wide Change Efforts. Madison: University of Wisconsin. http://www.oqi.wisc.edu/Showcase/Portals/0/CampusWideChange.pdf (ac- cessed January 13, 2009). USPHS (U.S. Public Health Service Commissioned Corps). 1995. Objectivity in research; final rule. Federal Register 60(132):35810-35819. USPSTF (U.S. Preventive Services Task Force). 2007a. Screening for lipid disorders in chil- dren: U.S. Preventive Services Task Force recommendation statement. Pediatrics 120(1): e215-e219.
282 CONFLICT OF INTEREST USPSTF. 2007b. Screening for Lipid Disorders in Children: U.S. Preventive Services Task Force Recommendation Statement. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/uspstf07/chlipid/chlipidrs.htm (accessed March 21, 2009). USPSTF. 2007c. Screening for Sickle Cell Disease in Newborns: U.S. Preventive Services Task Force Recommendation Statement. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/uspstf07/sicklecell/sicklers.htm (accessed April 25, 2008). USPSTF. 2008. Methods and Background: U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/uspstf08/ methods/procmanual.htm (accessed April 10, 2009). van Eijk, M. E., J. Avorn, A. J. Porsius, and A. de Boer. 2001. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus indi- vidual academic detailing. British Medical Journal 322(7287):654-657. Varley, C. K., M. D. Jibson, M. McCarthy, and S. Benjamin. 2005. A survey of the interac- tions between psychiatry residency programs and the pharmaceutical industry. Academic Psychiatry 29(1):40-46. Verkerk, K., H. Van Veenendaal, J. L. Severens, E. J. Hendriks, and J. S. Burgers. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2006. Con- sidered judgement in evidence-based guideline development. International Journal for Quality in Health Care 18(5):365-369. Vesely, R. 2005. Kaiser doctors conflict-of-interest policy tightened. Oakland Tribune, April 27. Vogeli, C., R. Yucel, E. Bendavid, L. M. Jones, M. S. Anderson, K. S. Louis, and E. G. Campbell. 2006. Data withholding and the next generation of scientists: results of a national survey. Academic Medicine 81(2):128-136. von Elm, E., D. G. Altman, M. Egger, S. J. Pocock, P. C. Gotzsche, and J. P. Vandenbroucke. 2007. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Medicine 4(10):e296. Vreman, H. J., R. J. Wong, J. R. Murdock, and D. K. Stevenson. 2008. Standardized bench method for evaluating the efficacy of phototherapy devices. Acta Paediatrica 97(3): 308-316. Wager, E. 2007. Authors, ghosts, damned lies, and statisticians. PLoS Medicine 4(1): e34-e35. Walker, L. 2001. ROI for Meetings Beats Detailing and DTC. http://meetingsnet.com/medi- calmeetings/meetings_roi_meetings_beats/ (accessed September 25, 2008). Wall, L. L., and D. Brown. 2007. The high cost of free lunch. Obstetrics and Gynecology 110(1):169-173. Wallack, T. 2008. Tied up over disclosure: life sciences firms anxious about rules on gifts to doctors. The Boston Globe, August 13, C1. WAME (World Association of Medical Editors). 2008. WAME Recommendations on Publica- tion Ethics Policies for Medical Journals. http://www.wame.org/resources/publication- ethics-policies-for-medical-journals#conflicts (accessed December 2, 2008). Warlow, C. 2007. No ghosts here please. Practical Neurology 7(2):72-73. Warner, T. D., and J. P. Gluck. 2003. What do we really know about conflicts of interest in biomedical research? Psychopharmacology 171(1):36-46. Warner, T. D., and L. W. Roberts. 2004. Scientific integrity, fidelity and conflicts of interest in research. Current Opinion in Psychiatry 17:381-385. Wartman, S. A. 2007. The Academic Health Center: Evolving Organizational Models. Wash- ington, DC: Association of Academic Health Centers. http://www.aahcdc.org/policy/ reddot/AAHC_Evolving_Organizational_Models.pdf (accessed August 12, 2008).
REFERENCES 283 Waters, R. 2006. J&J sued by Texas in whistleblower case on marketing (update1). Bloomberg Online News, December 28. http://www.bloomberg.com/apps/news?pid=20601202&sid =a2mpCNBojB2I&refer=healthcare (accessed April 25, 2008). Watson, P. Y., A. K. Khandelwal, J. L. Musial, and J. D. Buckley. 2005. Resident and faculty perceptions of conflict of interest in medical education. Journal of General Internal Medicine 20(4):357-359. Weber, M. 2006. Medicine and Conflicts of Interest: Creating a New Morality. http://www. medicalprogresstoday.com/spotlight/spotlight_indarchive.php?id=1399 (accessed Octo- ber 10, 2008). Wegman, A., D. van der Windt, M. van Tulder, W. Stalman, and T. de Vries. 2004. Nonste- roidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. Journal of Rheumatology 31(2):344-354. Weinfurt, K. P., J. Y. Friedman, J. S. Allsbrook, M. A. Dinan, M. A. Hall, and J. Sugarman. 2006a. Views of potential research participants on financial conflicts of interest: bar- riers and opportunities for effective disclosure. Journal of General Internal Medicine 21(9):901-906. Weinfurt, K. P., M. A. Dinan, J. S. Allsbrook, J. Y. Friedman, M. A. Hall, K. A. Schulman, and J. Sugarman. 2006b. Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants. Academic Medicine 81(2):113-118. Weinfurt, K. P., J. Y. Friedman, M. A. Dinan, J. S. Allsbrook, M. A. Hall, J. K. Dhillon, and J. Sugarman. 2006c. Disclosing conflicts of interest in clinical research: views of institu- tional review boards, conflict of interest committees, and investigators. Journal of Law, Medicine and Ethics 34(3):581-591, 481. Weinfurt, K. P., M. A. Hall, M. A. Dinan, V. DePuy, J. Y. Friedman, J. S. Allsbrook, and J. Sugarman. 2008a. Effects of disclosing financial interests on attitudes toward clinical research. Journal of General Internal Medicine 23(6):860-866. Weinfurt, K. P., M. A. Hall, J. Y. Friedman, C. Hardy, A. K. Fortune-Greeley, J. S. Lawlor, J. S. Allsbrook, L. Lin, K. A. Schulman, and J. Sugarman. 2008b. Effects of disclosing finan- cial interests on participation in medical research: a randomized vignette trial. American Heart Journal 156(4):689-697. Weinfurt, K. P., D. M. Seils, J. P. Tzeng, L. Lin, K. A. Schulman, and R. M. Califf. 2008c. Con- sistency of financial interest disclosures in the biomedical literature: the case of coronary stents. PLoS ONE 3(5):e2128. Weinmann, S., M. Koesters, and T. Becker. ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ 2007. Effects of implementation of psychiatric guidelines on provider performance and patient outcome: systematic review. Acta Psy- chiatrica Scandinavica 115(6):420-433. Weiss, R. 2005. NIH clears most researchers in conflict-of-interest probe. The Washington Post, February 23, A1. Wellman, H. R. 1967. Memorandum to the faculty and staff of the University of California on the university-wide statement on conflicts of interest. http://www.ucop.edu/ucophome/ coordrev/policy/10-05-67.html (accessed July 29, 2008). Wennberg, J. E. 2003. The more things change . . .: the federal governmentâs role in the evalu- ative sciences. Health Affairs Suppl. Web Exclusives:W3-308âW3-310. Werhane, P., and J. Doering. 1995. Conflicts of interest and conflicts of commitment. Profes- sional Ethics 4(3-4):47-81. Whelan, E. 2008. âConflictâ chills research. The Washington Times, April 8, A19. Whittington, C. J., T. Kendall, P. Fonagy, D. Cottrell, A. Cotgrove, and E. Boddington. 2004. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363(9418):1341-1345. Willman, D. 2004. The National Institutes of Health: public servant or private marketer? Los Angeles Times, December 22, A1.
284 CONFLICT OF INTEREST Willman, D. 2006. NIH audit criticizes scientistâs dealings. Los Angeles Times, September 10, A1. Wilson, J. W., C. M. Ott, K. Honer zu Bentrup, R. Ramamurthy, L. Quick, S. Porwollik, P. Cheng, et al. 2007. Space flight alters bacterial gene expression and virulence and reveals a role for global regulator Hfq. Proceedings of the National Academy of Sciences of the United States of America 104(41):16299-16304. Wimsatt, L., A. Trice, and R. Decker. 2005. Federal Demonstration Partnership: Fall 2005 Faculty Burden. http://thefdp.org/Faculty_Burden_Survey.pdf (accessed July 2, 2008). Witkin, K. B. 1997. Using pilot studies to chart a course in clinical research. Medical De- vice & Diagnostic Indaustry Magazine, June. http://www.devicelink.com/mddi/ archive/97/06/018.html (accessed March 2, 2009). WMS (Wisconsin Medical Society). 2008. Wisconsin Medical Society Board Passes New Physi- cian Gift Policy. Press release, October 16. Madison, WI: WMS. http://www.wisconsin- medicalsociety.org/publications_and_media/press_releases (accessed October 29, 2008). Woolf, S. H., R. Grol, A. Hutchinson, M. Eccles, and J. Grimshaw. 1999. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. British Medical Journal 318(7182):527-530. Woolley, K. L., J. A. Ely, M. J. Woolley, L. Findlay, F. A. Lynch, Y. Choi, and J. M. McDonald. 2006. Declaration of medical writing assistance in international peer-reviewed publica- tions. Journal of the American Medical Association 296(8):932-934. Wright, J. M., T. L. Perry, K. L. Bassett, and G. K. Chambers. 2001. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. Journal of the American Medical Associa- tion 286(19):2398-2400. Yank, V., D. Rennie, and L. A. Bero. 2007. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. British Medical Journal 335(7631):1202-1205. Zarin, D. A., T. Tse, and N. C. Ide. 2005. Trial registration at ClinicalTrials.gov between May and October 2005. New England Journal of Medicine 353(26):2779-2787. Zerhouni, E. 2007. Untitled. Presentation to the Institute of Medicine Committee on Conflicts of Interest in Medical Research, Education, and Practice, Washington, DC, November 6. Zerhouni, E. 2008. NIH response to OIG findings and recommendations. Appendix to the Office of Inspector General Report. In National Institutes of Health: Conflicts of Inter- est in Intramural Research. Bethesda, MD: National Institutes of Health. http://oig.hhs. gov/oei/reports/oei-03-06-00460.pdf (accessed June 23, 2008). Zipkin, D. A., and M. A. Steinman. 2005. Interactions between pharmaceutical representa- ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ tives and doctors in training. A thematic review. Journal of General Internal Medicine 20(8):777-786.